Prof Ali Zumla

Photo

Personal Profile

Name: Ali Zumla Email: a.zumla@ucl.ac.uk
Title: Prof Tel: +44-207-7940500
Department: Research Department of Infection Fax:
Position: Professor of Infectious Diseases and International Health Address: University College London, Royal Free Hospital Campus,Rowland Hill Street, London, NW3 2PF
Research Domain: Global Health, Infection, Immunology & Inflammation, Personalised Medicine, Populations & Lifelong Health Web Page: Personal Web Page

Profile

Research Description

GLOBAL/INTERNATIONAL R&D: 

1.CLINICAL TRIALS FOR EVALUATION NEW DIAGNOSTICS, DRUGS, TREATMENT AND PROPHYLACTICS: Professor Zumla has created major international multi-country collaborations between academia, health care providers and industry for the conduct of multi-centre GLP/GCP clinical trials, the results of which have changed global practice. Seven of 11 randomised clinical trials have been completed. A phase 1 trial of autologous bone-marrow-derived stem cell transfusions for treatment of MDR-TB in Belarus in collaboration with Professor Maeurer of Karolinska Institutet (PI) has been completed. A phase II trial is underway.

2. PATHOGENESIS STUDIES AND EPIDEMIOLOGICAL STUDIES: In 2002, a large autopsy study of 264 Zambian children undertaken by Prof.Zumla and colleagues yeilded high impact data on pathogenesis of killer respiratory tract infections. Sentinel epidemiological and clinical studies have shown the emergence of extensively drug resistant TB. Several autopsy and molecular studies of adults and children are ongoing.  

3. RESEARCH INTO THE EPIDEMIOLOGY, DIAGNOSIS, TREATMENT AND PREVENTION OF KILLER RESPIRATORY INFECTIONS ESP TB, TB/HIV AND MERS-COV: Laboratory and translational clinical research on longitudinal cohorts of patients is leading to development and evaluation of rapid diagnostics (urine, sputum and blood based) and biomarkers for diagnosis, response to treatment, cure and relapse. Novel biomarkers of cytokine ratios, urine and filter paper based TB diagnostics tests have been developed and current work focusses on development of new and novel rapid TB diagnostic technology, in inpatient settings in paediatric and adult wards. These data are novel show a huge clinical load of undiagnosed sub-clinical TB leading to new screening diagnostic algorithms and now call for more pro-active screening for TB at all points of care. 

UK/UCL BASED R&D:

1.TB IN LONDON: Professor Zumla pioneered The London TB Link R&D Project at a time when TB was thought not to be a problem in London.  His group’s data focussed UK governmental attention to the growing TB problem in London in immigrants, homeless and the elderly Research and advocacy activities on TB in has led to recognition of TB by the UK government as an important health issue with improved NHS TB services.

2.DEVELOPMENT OF RAPID DIAGNOSTIC TESTS FOR SEPSIS: Professor Zumla currently leads as PI several clinical translational TB projects including a 6 million euros EU-FW7 project on development of rapid diagnostic platforms for range respiratory tract pathogens linking industrial partners from France and Finland with hospitals in the UK and France. This will take forward the aim of developing point of care rapid diagnostics using multiplex platforms ‘sample in – answer out’’ within 1 hour for the diagnosis (including antibiotic resistance genes screening) of respiratory tract infections (RTIs) caused by a wide range of bacterial, viral and fungal pathogens from one sputum sample. Professor Zumla’s vision is to see this technology be powered by solar power so that it could be used at points of care in resource-poor tropical countries for accurate rapid diagnosis of RTI’s. 


Research Activities

Clinical trials

Development and evaluation of rapid point of care diagnostics

Evaluation and development of newer TB diagnostics in HIV-infected children and adults with TB

Infectious diseases

Microorganisms and immunoregulation

Molecular diagnostics

Optimal timing of HAART therapy in HIV-i etc

Pathogenesis and autopsy studies

R&D in poverty related killer diseases TB, HV/AIDS

Rapid diagnostics for endocarditis

Education Description

1. Undergraduate Medical students: Infectious diseases/microbiology/tropical Medicine/Clinical bedside 2. Supervision of PhD students 3. Supervision of postdoctoral scientists 

2. Visitng Professor to the several Institutions eg: Institute of Child Health, London; University of Zambia School of Medicine;Lusaka, Zambia; University of Cape Town, South Africa; Liverpool School of Medicine; University of Amsterdam; Karolinska Institutet.

3. External examiner for MSc and PhDs to several national and international universities.     

4. BOOKS AND SPECIALIST JOURNAL VOLUMES:  

A) TEXTBOOKS: Editor of 18 textbooks including MRCP Part 1, MRCP Part 2, Granulomatous Disorders; Return of the White Plague; Clinics in Chest Medicine -Tuberculosis; Infectious Diseases Clinics of North America vols x 3; the global 'classics a) Manson's Tropical Diseases,21st and 22nd editions b) Tuberculosis- a comprehensive Clinical Reference. 

B) JOURNALS: Several eg: a. Lancet Infectious Diseases b. Current Opinion in Pulmonary Medicine, c. Editor, COPM Infectious Diseases volume, d. IDClinics North America                        

5. GLOBAL HEALTH CURRICULUM DEVELOPMENT: Founder member with Prof J.Yudkin, of IHMEC-Intl Health Medical Education Centre at UCL-SSMs in international health, intercalated BSC in International health at UCL  

6. TEACHING THROUGH HIGH PROFILE JOURNAL THEME SERIES: 1. Lead 'guru' Lancet TB Theme series (2010), 2. Chief Guest Editor Journal of Infectious diseases volume on TB, TB/HIV/AIDS-unanswered questions and controversies 2012, 3. Guest editor, Lancet Infectious Diseases series on Tuberculosis (2013).

UCL Collaborators

Dr Patrick Phillips; Dr Bridget Ferns; Prof Tom Rademacher; Prof Janet Darbyshire; Prof Andrew Tomkins; Prof Richard Tedder; Prof Graham Rook; Dr James Huggett; Dr Jeremy Garson; Prof Matthew Gandy; Dr Mahdad Noursadeghi; Prof Timothy Mchugh; Prof Andrew Nunn

External Collaborators

Publications

    2014

    • Enne VI, Personne Y, Grgic L, Gant V, Zumla A (2014). Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance. Current Opinion in Pulmonary Medicine, 20(3), 252 - 258. doi:10.1097/MCP.0000000000000042
    • Hui DS, Zumla A (2014). Advancing priority research on the middle east respiratory syndrome coronavirus. Journal of Infectious Diseases, 209(2), 173 - 176. doi:10.1093/infdis/jit591
    • Zumla A (2014). New developments in the epidemiology, diagnosis, treatment and prevention of respiratory tract infections. Current Opinion in Pulmonary Medicine, 20(3), 213 - 214. doi:10.1097/MCP.0000000000000055
    • Zumla AI, Schito M, Maeurer M (2014). Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines. The Lancet Infectious Diseases, 14(4), 267 - 269. doi:10.1016/S1473-3099(14)70028-3
    • Herbert N, George A, Masham Of Ilton B, Sharma V, Oliver M, Oxley A, Raviglione M, Zumla AI (2014). World TB Day 2014: Finding the missing 3 million. The Lancet, 383(9922), 1016 - 1018. doi:10.1016/S0140-6736(13)62675-6
    • Zumla A (2014). New developments in the epidemiology, diagnosis, treatment and prevention of respiratory tract infections. Current Opinion in Pulmonary Medicine, , - . doi:10.1097/MCP.0000000000000055
    • Kaufmann SHE, Lange C, Balaji KN, Lotze M, Schito M, Zumla AI, Rao M, Maeurer M (2014). Progress in tuberculosis vaccine development and host-directed therapies-a state of the art review. The Lancet Respiratory Medicine, , - . doi:10.1016/S2213-2600(14)70033-5
    • Maeurer M, Schito M, Zumla A (2014). Totally-drug-resistant tuberculosis: hype versus hope. The Lancet Respiratory Medicine, , - . doi:10.1016/S2213-2600(14)70020-7
    • Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ (2014). New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects.. Lancet Infect Dis, 14(4), 327 - 340. doi:10.1016/S1473-3099(13)70328-1
    • Skrahin A, Skrahina A, Ahmed RK, Ferrara G, Rane L, Maeurer MJ, Poiret T, Isaikina Y, Zumla A (2014). Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: An open-label phase 1 safety trial. The Lancet Respiratory Medicine, 2(2), 108 - 122. doi:10.1016/S2213-2600(13)70234-0
    • Enne VI, Personne Y, Grgic L, Gant V, Zumla A (2014). Aetiology of hospital-acquired pneumonia and trends in antimicrobial resistance. Current Opinion in Pulmonary Medicine, , - . doi:10.1097/MCP.0000000000000042
    • Hui DS, Memish ZA, Zumla A (2014). Severe acute respiratory syndrome vs. The middle east respiratory syndrome. Current Opinion in Pulmonary Medicine, , - . doi:10.1097/MCP.0000000000000046
    • Lechartier B, Rybniker J, Cole ST, Zumla A (2014). Tuberculosis drug discovery in the post-post-genomic era. EMBO Molecular Medicine, 6(2), 158 - 168. doi:10.1002/emmm.201201772
    • Memish ZA, Al-Rabeeah AA, Assiri A, Alhakeem RF, Zumla A, Al-Tawfiq JA, Makhdoom HQ, Alrabiah FA, Al Hajjar S, Albarrak A, Flemban H, Balkhy H, Barry M, Alhassan S, Alsubaie S (2014). Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: A prospective descriptive study. Clinical Microbiology and Infection, , - . doi:10.1111/1469-0691.12562
    • Skrahin A, Skrahina A, Ahmed RK, Ferrara G, Rane L, Maeurer MJ, Poiret T, Isaikina Y, Zumla A (2014). Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. The Lancet Respiratory Medicine, , - . doi:10.1016/S2213-2600(13)70234-0
    • Hui DS, Memish ZA, Zumla A (2014). Severe acute respiratory syndrome vs. The Middle East respiratory syndrome. Current Opinion in Pulmonary Medicine, 20(3), 233 - 241. doi:10.1097/MCP.0000000000000046

    2013

    • Zumla A, Bates M, Gant V, Mwaba P, Maeurer M, Memish ZA (2013). Rapid diagnostics urgently needed for killer infections. The Lancet Respiratory Medicine, 1(4), 284 - 285. doi:10.1016/S2213-2600(13)70099-7
    • Assiri A, Al-Rabeeah AA, Al-Hakeem RF, Zumla AI, Memish ZA, Al-Tawfiq JA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Makhdoom HQ (2013). Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet Infectious Diseases, , - . doi:10.1016/S1473-3099(13)70204-4
    • Bates M, Ahmed Y, Chilukutu L, Tembo J, Cheelo B, Sinyangwe S, Kapata N, Maeurer M, O'Grady J, Mwaba P, Zumla A (2013). Use of the Xpert® MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia. Tropical Medicine and International Health, , - .
    • Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM (2013). Family cluster of middle east respiratory syndrome coronavirus infections. New England Journal of Medicine, 368(26), 2487 - 2494.
    • Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, Phillips PP, Venter A, Bateson A, Boehme CC, Heinrich N, Hunt RD, Boeree MJ, Zumla A, McHugh TD, Gillespie SH, Diacon AH, Hoelscher M (2013). Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. The Lancet Respiratory Medicine, , - .
    • Zumla A (2013). Current trends and newer concepts on diagnosis, management and prevention of respiratory tract infections. Current Opinion in Pulmonary Medicine, 19(3), 189 - 191.
    • Bates M, Mudenda V, Mwaba P, Zumla A (2013). Deaths due to respiratory tract infections in africa: A review of autopsy studies. Current Opinion in Pulmonary Medicine, 19(3), 229 - 237.
    • Reddington K, Tuite N, Barry T, O'Grady J, Zumla A (2013). Advances in multiparametric molecular diagnostics technologies for respiratory tract infections. Current Opinion in Pulmonary Medicine, 19(3), 298 - 304.
    • Al-Tawfiq JA, Zumla A, Memish ZA (2013). Respiratory tract infections during the annual Hajj: Potential risks and mitigation strategies. Current Opinion in Pulmonary Medicine, 19(3), 192 - 197.
    • Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M (2013). Drug-resistant tuberculosis: Time for visionary political leadership. The Lancet Infectious Diseases, 13(6), 529 - 539.
    • Zumla A, Gant V, Bates M, Mwaba P, Maeurer M, Memish ZA (2013). Rapid diagnostics urgently needed for killer infections. The Lancet Respiratory Medicine, , - .
    • Marais BJ, Lönnroth K, Glaziou P, Lawn SD, Migliori GB, Mwaba P, Bates M, Zumla A, Zijenah L, Colagiuri R, Swaminathan S, Memish ZA, Pletschette M, Hoelscher M, Hasan R, Zafar A, Abubakar I, Pantaleo G, Craig G, Kim P, Maeurer M, Schito M (2013). Tuberculosis comorbidity with communicable and non-communicable diseases: Integrating health services and control efforts. The Lancet Infectious Diseases, 13(5), 436 - 448. doi:10.1016/S1473-3099(13)70015-X
    • Wells WA, Gardiner E, Mdluli K, Boehme CC, Perkins MD, Cobelens FGJ, Daniels C, Dowdy D, Gheuens J, Kimerling ME, Kim P, Kreiswirth B, Lienhardt C, Zignol M, Pai M, Peter T, Zumla A, Schito M (2013). Alignment of new tuberculosis drug regimens and drug susceptibility testing: A framework for action. The Lancet Infectious Diseases, 13(5), 449 - 458. doi:10.1016/S1473-3099(13)70025-2
    • Zumla A, Nahid P, Cole ST (2013). Advances in the development of new tuberculosis drugs and treatment regimens.. Nat Rev Drug Discov, 12(5), 388 - 404. doi:10.1038/nrd4001
    • Wallis RS, Kim P, Andrade BB, Cole S, Hanna D, Maeurer M, Schito M, Zumla A (2013). Tuberculosis biomarkers discovery: Developments, needs, and challenges. The Lancet Infectious Diseases, 13(4), 362 - 372. doi:10.1016/S1473-3099(13)70034-3
    • Lawn SD, McNerney R, Mwaba P, Bates M, Kapata N, Zumla A, McHugh TD, Abubakar I, Piatek A, Alexander H, Marais BJ, Cuevas LE, Zijenah L, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M (2013). Advances in tuberculosis diagnostics: The Xpert MTB/RIF assay and future prospects for a point-of-care test. The Lancet Infectious Diseases, 13(4), 349 - 361. doi:10.1016/S1473-3099(13)70008-2
    • Marais BJ, Graham SM, Maeurer M, Zumla A (2013). Progress and challenges in childhood tuberculosis. The Lancet Infectious Diseases, 13(4), 287 - 289. doi:10.1016/S1473-3099(13)70031-8
    • Zumla A, Kim P, Maeurer M, Schito M (2013). Zero deaths from tuberculosis: Progress, reality, and hope. The Lancet Infectious Diseases, 13(4), 285 - 287. doi:10.1016/S1473-3099(13)70039-2
    • Ivanyi J, Zumla A (2013). Nonsteroidal antiinflammatory drugs for adjunctive tuberculosis treatment.. J Infect Dis, 208(2), 185 - 188. doi:10.1093/infdis/jit153
    • Rakotosamimanana N, Doherty TM, Andriamihantasoa LH, Richard V, Gicquel B, Soares JL, Zumla A, Razanamparany VR (2013). Expression of TNF-alpha-dependent apoptosis-related genes in the peripheral blood of Malagasy subjects with tuberculosis.. PLoS One, 8(4), e61154 - . doi:10.1371/journal.pone.0061154
    • Brodin P, Valentini D, Uhlin M, Mattsson J, Zumla A, Maeurer MJ (2013). Systems level immune response analysis and personalized medicine.. Expert Rev Clin Immunol, 9(4), 307 - 317. doi:10.1586/eci.13.9
    • Axelsson-Robertson R, Loxton AG, Walzl G, Ehlers MM, Kock MM, Zumla A, Maeurer M (2013). A broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis.. PLoS One, 8(3), e58309 - . doi:10.1371/journal.pone.0058309
    • Zumla A, Kim P, Maeurer M, Schito M (2013). Zero deaths from tuberculosis: progress, reality, and hope.. Lancet Infect Dis, 13(4), 285 - 287. doi:10.1016/S1473-3099(13)70039-2
    • Marais BJ, Graham SM, Maeurer M, Zumla A (2013). Progress and challenges in childhood tuberculosis.. Lancet Infect Dis, 13(4), 287 - 289. doi:10.1016/S1473-3099(13)70031-8
    • Wallis RS, Kim P, Cole S, Hanna D, Andrade BB, Maeurer M, Schito M, Zumla A (2013). Tuberculosis biomarkers discovery: developments, needs, and challenges.. Lancet Infect Dis, 13(4), 362 - 372. doi:10.1016/S1473-3099(13)70034-3
    • Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M (2013). Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.. Lancet Infect Dis, 13(5), 449 - 458. doi:10.1016/S1473-3099(13)70025-2
    • Marais BJ, Lönnroth K, Lawn SD, Migliori GB, Mwaba P, Glaziou P, Bates M, Colagiuri R, Zijenah L, Swaminathan S, Memish ZA, Pletschette M, Hoelscher M, Abubakar I, Hasan R, Zafar A, Pantaleo G, Craig G, Kim P, Maeurer M, Schito M, Zumla A (2013). Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts.. Lancet Infect Dis, 13(5), 436 - 448. doi:10.1016/S1473-3099(13)70015-X
    • Abubakar I, Zignol M, Falzon D, Raviglione M, Ditiu L, Masham S, Adetifa I, Ford N, Cox H, Lawn SD, Marais BJ, McHugh TD, Mwaba P, Bates M, Lipman M, Zijenah L, Logan S, McNerney R, Zumla A, Sarda K, Nahid P, Hoelscher M, Pletschette M, Memish ZA, Kim P, Hafner R, Cole S, Migliori GB, Maeurer M, Schito M, Zumla A (2013). Drug-resistant tuberculosis: time for visionary political leadership.. Lancet Infect Dis, 13(6), 529 - 539. doi:10.1016/S1473-3099(13)70030-6
    • Lawn SD, Mwaba P, Bates M, Piatek A, Alexander H, Marais BJ, Cuevas LE, McHugh TD, Zijenah L, Kapata N, Abubakar I, McNerney R, Hoelscher M, Memish ZA, Migliori GB, Kim P, Maeurer M, Schito M, Zumla A (2013). Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test.. Lancet Infect Dis, 13(4), 349 - 361. doi:10.1016/S1473-3099(13)70008-2
    • McCloskey B, Zumla A, Stephens G, Heymann DL, Memish ZA (2013). Applying lessons from SARS to a newly identified coronavirus.. Lancet Infect Dis, 13(5), 384 - 385. doi:10.1016/S1473-3099(13)70082-3
    • Alvarez-Corrales N, Rodriguez CA, Rivera R, Pineda-Garcia L, Maeurer M, Ahmed RK, Hoffner SE, Balaji KN, Sompallae R, Vudattu NK, Zumla A (2013). Differential cellular recognition pattern to M. tuberculosis targets defined by IFN-γ and IL-17 production in blood from TB + patients from Honduras as compared to health care workers: TB and immune responses in patients from Honduras. BMC Infectious Diseases, 13(1), - . doi:10.1186/1471-2334-13-125
    • Al-Hajoj S, Varghese B, Shoukri MM, Al-Omari R, Al-Herbwai M, Alrabiah F, Alrajhi AA, Abuljadayel N, Al-Thawadi S, Zumla A, Zignol M, Raviglione MC, Memish Z (2013). Epidemiology of antituberculosis drug resistance in Saudi Arabia: findings of the first national survey.. Antimicrob Agents Chemother, 57(5), 2161 - 2166. doi:10.1128/AAC.02403-12
    • Zumla A, Raviglione M, Hafner R, von Reyn CF (2013). Tuberculosis.. N Engl J Med, 368(8), 745 - 755. doi:10.1056/NEJMra1200894
    • Zumla A (2013). Current trends and newer concepts on diagnosis, management and prevention of respiratory tract infections.. Curr Opin Pulm Med, 19(3), 189 - 191. doi:10.1097/MCP.0b013e32835f8265
    • Reddington K, Tuite N, Barry T, O'Grady J, Zumla A (2013). Advances in multiparametric molecular diagnostics technologies for respiratory tract infections.. Curr Opin Pulm Med, 19(3), 298 - 304. doi:10.1097/MCP.0b013e32835f1b32
    • Al-Tawfiq JA, Zumla A, Memish ZA (2013). Respiratory tract infections during the annual Hajj: potential risks and mitigation strategies.. Curr Opin Pulm Med, 19(3), 192 - 197. doi:10.1097/MCP.0b013e32835f1ae8
    • Bates M, Mudenda V, Mwaba P, Zumla A (2013). Deaths due to respiratory tract infections in Africa: a review of autopsy studies.. Curr Opin Pulm Med, 19(3), 229 - 237. doi:10.1097/MCP.0b013e32835f4fe4
    • Marais BJ, Zumla A (2013). History of tuberculosis and drug resistance.. N Engl J Med, 368(1), 88 - . doi:10.1056/NEJMc1212308#SA1
    • Kapata N, Chanda-Kapata P, O'Grady J, Bates M, Mwaba P, Janssen S, Marais B, Cobelens F, Grobusch M, Zumla A (2013). Trends in childhood tuberculosis in Zambia: a situation analysis.. J Trop Pediatr, 59(2), 134 - 139. doi:10.1093/tropej/fms065
    • Bates M, O'Grady J, Zumla A, Tembo J, Chilukutu L, Kasonde R, Mulota P, Mzyece J, Chomba M, Mukonda L, Mumba M, Kapata N, Mwaba P, Maeurer M, Chabala C, Rachow A, Clowes P, Hoelscher M (2013). Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: A prospective descriptive study. The Lancet Infectious Diseases, 13(1), 36 - 42. doi:10.1016/S1473-3099(12)70245-1
    • Mwaanza N, Chilukutu L, Tembo J, Kabwe M, Musonda K, Kapasa M, Chabala C, Sinyangwe S, Mwaba P, Zumla A, Bates M (2013). High rates of congenital cytomegalovirus (CMV) infections linked with maternal HIV infection among neonatal admissions at a large referral centre in sub-Saharan Africa.. Clin Infect Dis, , - . doi:10.1093/cid/cit766
    • Assiri A, Alhakeem RF, AlRabiah FA, Zumla AI, Memish ZA, Cotten M, Watson SJ, Kellam P, Palser AL, Gall A, Bashford-Rogers R, Makhdoom HQ, Madani H, Aal-Tawfiq J, Rambaut A, Al-Rabeeah AA, Hajjar SA, Al-Nassir WN, Albarrak A, Flemban H, Balkhy HH, Alsubaie S (2013). Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: A descriptive genomic study. The Lancet, 382(9909), 1993 - 2002. doi:10.1016/S0140-6736(13)61887-5
    • Zumla A, George A, Sharma V (2013). WHO's 2013 global report on tuberculosis: Successes, threats, and opportunities. The Lancet, 382(9907), 1765 - 1767. doi:10.1016/S0140-6736(13)62078-4
    • Zumla A, George A, Sharma V, Herbert N, Baroness MOI (2013). WHO's 2013 global report on tuberculosis: successes, threats, and opportunities. The Lancet, , - . doi:10.1016/S0140-6736(13)62078-4
    • Kapata N, Chanda-Kapata P, Mwaba P, Bates M, Zumla A, Cobelens F, Grobusch MP (2013). Multidrug-resistant TB in Zambia: Review of national data from 2000 to 2011. Tropical Medicine and International Health, 18(11), 1386 - 1391. doi:10.1111/tmi.12183
    • Zenner D, Zumla A, Gill P, Cosford P, Abubakar I (2013). Reversing the tide of the UK tuberculosis epidemic.. Lancet, 382(9901), 1311 - 1312. doi:10.1016/S0140-6736(13)62113-3
    • Memish ZA, Zumla A, Al-Tawfiq JA (2013). How great is the risk of Middle East respiratory syndrome coronavirus to the global population?. Expert Rev Anti Infect Ther, 11(10), 979 - 981. doi:10.1586/14787210.2013.836965
    • Al-Rabeeah AA, Assiri A, Alhakeem RF, Zumla AI, Memish ZA, Cotten M, Watson SJ, Kellam P, Palser AL, Gall A, Bashford-Rogers R, Makhdoom HQ, Madani H, Al-Tawfiq JA, Rambaut A, AlRabiah FA, Hajjar SA, Al-nassir WN, Albarrak A, Flemban H, Balkhy HH, Alsubaie S (2013). Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study. The Lancet, , - . doi:10.1016/S0140-6736(13)61887-5
    • Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA (2013). Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy. International Journal of Infectious Diseases, 17(10), - . doi:10.1016/j.ijid.2013.07.002
    • Kapata N, Chanda-Kapata P, Bates M, Mwaba P, Cobelens F, Grobusch MP, Zumla A (2013). Multidrug-resistant TB in Zambia: review of national data from 2000 to 2011.. Trop Med Int Health, , - . doi:10.1111/tmi.12183
    • Memish ZA, Assiri A, Zumla AI (2013). Middle East respiratory syndrome coronavirus infections in health care workers. New England Journal of Medicine, 369(9), 884 - 886. doi:10.1056/NEJMc1308698
    • Assiri A, Al-Rabeeah AA, Al-Hakeem RF, Zumla AI, Memish ZA, Al-Tawfiq JA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemban H, Al-Nassir WN, Balkhy HH, Makhdoom HQ (2013). Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. The Lancet Infectious Diseases, 13(9), 752 - 761. doi:10.1016/S1473-3099(13)70204-4
    • Bates M, O'Grady J, Zumla A, Chilukutu L, Tembo J, Cheelo B, Kapata N, Mwaba P, Ahmed Y, Sinyangwe S, Maeurer M (2013). Use of the Xpert MTB/RIF assay for diagnosing pulmonary tuberculosis comorbidity and multidrug-resistant TB in obstetrics and gynaecology inpatient wards at the University Teaching Hospital, Lusaka, Zambia. Tropical Medicine and International Health, 18(9), 1134 - 1140. doi:10.1111/tmi.12145
    • Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA (2013). Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - possible lessons from a systematic review of SARS-CoV therapy.. Int J Infect Dis, , - . doi:10.1016/j.ijid.2013.07.002
    • Sotgiu G, Centis R, D'Ambrosio L, Spanevello A, Migliori GB, Alffenaar JWC, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Linezolid IGS (2013). Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. EUROPEAN RESPIRATORY JOURNAL, 42(1), 288 - 290. doi:10.1183/09031936.00191712
    • Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, Alabdullatif ZN, Assad M, Almulhim A, Makhdoom H, Madani H, Alhakeem R, Al-Tawfiq JA, Cotten M, Watson SJ, Kellam P, Zumla AI, Memish ZA, the KSA MERS-CoV Investigation Team (2013). Hospital Outbreak of Middle East Respiratory Syndrome Coronavirus.. N Engl J Med, , - . doi:10.1056/NEJMoa1306742

    2012

    • Sotgiu G, Centis R, D'Ambrosio L, Alffenaar J-WC, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh W-J, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger J-P, Zumla A, Migliori GB (2012). Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. European Respiratory Journal, 40(6), 1430 - 1442.
    • Abubakar I, Dara M, Manissero D, Zumla A (2012). Tackling the spread of drug-resistant tuberculosis in Europe.. Lancet, 379(9813), e21 - e23. doi:10.1016/S0140-6736(11)61428-1
    • Bates M, O'Grady J, Maeurer M, Tembo J, Chilukutu L, Chabala C, Kasonde R, Mulota P, Mzyece J, Chomba M, Mukonda L, Mumba M, Kapata N, Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A (2012). Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis, , - . doi:10.1016/S1473-3099(12)70245-1
    • Kapata N, Chanda-Kapata P, Grobusch MP, O'Grady J, Bates M, Mwaba P, Zumla A (2012). Leprosy trends in Zambia 1991-2009.. Trop Med Int Health, 17(10), 1289 - 1293. doi:10.1111/j.1365-3156.2012.03050.x
    • O'Grady J, Bates M, Chilukutu L, Mzyece J, Cheelo B, Chilufya M, Mukonda L, Mumba M, Tembo J, Chomba M, Kapata N, Maeurer M, Rachow A, Clowes P, Hoelscher M, Mwaba P, Zumla A (2012). Evaluation of the Xpert MTB/RIF Assay at a Tertiary Care Referral Hospital in a Setting Where Tuberculosis and HIV Infection Are Highly Endemic.. Clin Infect Dis, 55(9), 1171 - 1178. doi:10.1093/cid/cis631
    • Zumla A, Keiser J (2012). Preface: tropical diseases.. Infect Dis Clin North Am, 26(2), xv - xvii. doi:10.1016/j.idc.2012.03.012
    • Zumla A, Ustianowski A (2012). Tropical diseases: definition, geographic distribution, transmission, and classification.. Infect Dis Clin North Am, 26(2), 195 - 205. doi:10.1016/j.idc.2012.02.007
    • Raviglione M, Marais B, Floyd K, Lönnroth K, Getahun H, Migliori GB, Harries AD, Nunn P, Lienhardt C, Graham S, Chakaya J, Weyer K, Cole S, Kaufmann SH, Zumla A (2012). Scaling up interventions to achieve global tuberculosis control: progress and new developments.. Lancet, 379(9829), 1902 - 1913. doi:10.1016/S0140-6736(12)60727-2
    • Reddington K, Zumla A, Bates M, van Soolingen D, Niemann S, Barry T, O'Grady J (2012). SeekTB, a two-stage multiplex real-time-PCR-based method for differentiation of the Mycobacterium tuberculosis complex.. J Clin Microbiol, 50(7), 2203 - 2206. doi:10.1128/JCM.00718-12
    • Geldmacher C, Zumla A, Hoelscher M (2012). Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis.. Curr Opin HIV AIDS, 7(3), 268 - 275. doi:10.1097/COH.0b013e3283524e32
    • Cummings I, O'Grady J, Pai V, Kolvekar S, Zumla A (2012). Surgery and tuberculosis.. Curr Opin Pulm Med, 18(3), 241 - 245. doi:10.1097/MCP.0b013e3283521391
    • Sotgiu G, Centis R, D'Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, Schecter GF, Shim TS, Singla R, Skrahina A, Spanevello A, Udwadia ZF, Villar M, Zampogna E, Zellweger JP, Zumla A, Migliori GB (2012). Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis.. Eur Respir J, 40(6), 1430 - 1442. doi:10.1183/09031936.00022912
    • McNerney R, Maeurer M, Abubakar I, Marais B, McHugh TD, Ford N, Weyer K, Lawn S, Grobusch MP, Memish Z, Squire SB, Pantaleo G, Chakaya J, Casenghi M, Migliori GB, Mwaba P, Zijenah L, Hoelscher M, Cox H, Swaminathan S, Kim PS, Schito M, Harari A, Bates M, Schwank S, O'Grady J, Pletschette M, Ditui L, Atun R, Zumla A (2012). Tuberculosis diagnostics and biomarkers: needs, challenges, recent advances, and opportunities.. J Infect Dis, 205 Suppl 2, S147 - S158. doi:10.1093/infdis/jir860
    • Kapata N, Chanda-Kapata P, Grobusch MP, O'Grady J, Schwank S, Bates M, Jansenn S, Mwinga A, Cobelens F, Mwaba P, Zumla A (2012). Scale-up of TB and HIV programme collaborative activities in Zambia - a 10-year review.. Trop Med Int Health, 17(6), 760 - 766. doi:10.1111/j.1365-3156.2012.02981.x
    • Zumla A, Abubakar I, Raviglione M, Hoelscher M, Ditiu L, McHugh TD, Squire SB, Cox H, Ford N, McNerney R, Marais B, Grobusch M, Lawn SD, Migliori GB, Mwaba P, O'Grady J, Pletschette M, Ramsay A, Chakaya J, Schito M, Swaminathan S, Memish Z, Maeurer M, Atun R (2012). Drug-resistant tuberculosis--current dilemmas, unanswered questions, challenges, and priority needs.. J Infect Dis, 205 Suppl 2, S228 - S240. doi:10.1093/infdis/jir858
    • Migliori GB, Zellweger JP, Abubakar I, Ibraim E, Caminero JA, De Vries G, D'Ambrosio L, Centis R, Sotgiu G, Menegale O, Kliiman K, Aksamit T, Cirillo DM, Danilovits M, Dara M, Dheda K, Dinh-Xuan AT, Kluge H, Lange C, Leimane V, Loddenkemper R, Nicod LP, Raviglione MC, Spanevello A, Thomsen VØ, Villar M, Wanlin M, Wedzicha JA, Zumla A, Blasi F, Huitric E, Sandgren A, Manissero D (2012). European union standards for tuberculosis care.. Eur Respir J, 39(4), 807 - 819. doi:10.1183/09031936.00203811
    • Zumla A, Blasi F, Raviglione M (2012). Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance.. Eur Respir J, 39(4), 802 - 804. doi:10.1183/09031936.00171611
    • Uhlin M, Andersson J, Zumla A, Maeurer M (2012). Adjunct immunotherapies for tuberculosis.. J Infect Dis, 205 Suppl 2, S325 - S334. doi:10.1093/infdis/jis197
    • Akachi Y, Zumla A, Atun R (2012). Investing in improved performance of national tuberculosis programs reduces the tuberculosis burden: analysis of 22 high-burden countries, 2002-2009.. J Infect Dis, 205 Suppl 2, S284 - S292. doi:10.1093/infdis/jis189
    • Raviglione M, Zumla A, Marais B, Horton R, Motsoaledi A (2012). A sustainable agenda for tuberculosis control and research.. Lancet, 379(9821), 1077 - 1078. doi:10.1016/S0140-6736(12)60373-0
    • Abubakar I, Stagg HR, Cohen T, Mangtani P, Rodrigues LC, Pimpin L, Watson JM, Squire SB, Zumla A (2012). Controversies and unresolved issues in tuberculosis prevention and control: a low-burden-country perspective.. J Infect Dis, 205 Suppl 2, S293 - S300. doi:10.1093/infdis/jir886
    • Zumla A, Atun R, Maeurer M, Kim PS, Jean-Philippe P, Hafner R, Schito M (2012). Eliminating tuberculosis and tuberculosis-HIV co-disease in the 21st century: key perspectives, controversies, unresolved issues, and needs.. J Infect Dis, 205 Suppl 2, S141 - S146. doi:10.1093/infdis/jir880
    • Lee D, Lal SS, Komatsu R, Zumla A, Atun R (2012). Global fund financing of tuberculosis services delivery in prisons.. J Infect Dis, 205 Suppl 2, S274 - S283. doi:10.1093/infdis/jis042
    • Phillips PP, Gillespie SH, Boeree M, Heinrich N, Aarnoutse R, McHugh T, Pletschette M, Lienhardt C, Hafner R, Mgone C, Zumla A, Nunn AJ, Hoelscher M (2012). Innovative trial designs are practical solutions for improving the treatment of tuberculosis.. J Infect Dis, 205 Suppl 2, S250 - S257. doi:10.1093/infdis/jis041
    • Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, Hoelscher M, Zumla A, Gheuens J (2012). New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future.. J Infect Dis, 205 Suppl 2, S241 - S249. doi:10.1093/infdis/jis034
    • Zumla A, Maeurer M (2012). Rational development of adjunct immune-based therapies for drug-resistant tuberculosis: hypotheses and experimental designs.. J Infect Dis, 205 Suppl 2, S335 - S339. doi:10.1093/infdis/jir881
    • Axelsson-Robertson R, Magalhaes I, Parida SK, Zumla A, Maeurer M (2012). The immunological footprint of Mycobacterium tuberculosis T-cell epitope recognition.. J Infect Dis, 205 Suppl 2, S301 - S315. doi:10.1093/infdis/jis198
    • Mudenda V, Lucas S, Shibemba A, O'Grady J, Bates M, Kapata N, Schwank S, Mwaba P, Atun R, Hoelscher M, Maeurer M, Zumla A (2012). Tuberculosis and tuberculosis/HIV/AIDS-associated mortality in Africa: the urgent need to expand and invest in routine and research autopsies.. J Infect Dis, 205 Suppl 2, S340 - S346. doi:10.1093/infdis/jir859
    • Haroon A, Zumla A, Bomanji J (2012). Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders.. Clin Infect Dis, 54(9), 1333 - 1341. doi:10.1093/cid/cis193
    • Zumla A, Cobelens F (2012). Operational research and MDG tuberculosis control targets.. Lancet Infect Dis, 12(4), 262 - 263. doi:10.1016/S1473-3099(12)70034-8
    • Ferrara G, Murray M, Winthrop K, Centis R, Sotgiu G, Migliori GB, Maeurer M, Zumla A (2012). Risk factors associated with pulmonary tuberculosis: smoking, diabetes and anti-TNFα drugs.. Curr Opin Pulm Med, 18(3), 233 - 240. doi:10.1097/MCP.0b013e328351f9d6
    • Zumla A (2012). Killer respiratory tract infections: time to turn the tide.. Curr Opin Pulm Med, 18(3), 173 - 174. doi:10.1097/MCP.0b013e328351f7d8
    • Ahmed RK, Rohava Z, Balaji KN, Hoffner SE, Gaines H, Magalhaes I, Zumla A, Skrahina A, Maeurer MJ (2012). Pattern recognition and cellular immune responses to novel Mycobacterium tuberculosis-antigens in individuals from Belarus.. BMC Infect Dis, 12, 41 - . doi:10.1186/1471-2334-12-41
    • Masukume G, Zumla A (2012). Analogies and metaphors in clinical medicine.. Clin Med, 12(1), 55 - 56.
    • Zumla A, Hafner R, Lienhardt C, Hoelscher M, Nunn A (2012). Advancing the development of tuberculosis therapy.. Nat Rev Drug Discov, 11(3), 171 - 172. doi:10.1038/nrd3694
    • Lawn SD, Zumla AI (2012). Diagnosis of extrapulmonary tuberculosis using the Xpert MTB/RIF assay. Expert Review of Anti-Infective Therapy, 10(6), 631 - 635. doi:10.1586/eri.12.43
    • Ustianowski A, Zumla A (2012). Eosinophilia in the Returning Traveler. Infectious Disease Clinics of North America, 26(3), 781 - 789. doi:10.1016/j.idc.2012.05.004
    • Bates M, O'Grady J, Mwaba P, Chilukutu L, Mzyece J, Cheelo B, Chilufya M, Mukonda L, Mumba M, Tembo J, Chomba M, Kapata N, Rachow A, Clowes P, Maeurer M, Hoelscher M, Zumla A (2012). Evaluation of the burden of unsuspected pulmonary tuberculosis and co-morbidity with non-communicable diseases in sputum producing adult inpatients.. PLoS One, 7(7), e40774 - . doi:10.1371/journal.pone.0040774
    • O'Grady J, Bates M, Zumla A, Chilukutu L, Mzyece J, Cheelo B, Chilufya M, Mukonda L, Mumba M, Tembo J, Chomba M, Kapata N, Mwaba P, Maeurer M, Rachow A, Clowes P, Hoelscher M (2012). Evaluation of the xpert MTB/RIF assay at a tertiary care referral hospital in a setting where tuberculosis and hiv infection are highly endemic. Clinical Infectious Diseases, 55(9), 1171 - 1178. doi:10.1093/cid/cis631
    • Al Mazroa MA, Kabbash IA, Felemban SM, Stephens GM, Al-Hakeem RF, Memish ZA, Zumla AI (2012). HIV Case Notification Rates in the Kingdom of Saudi Arabia over the Past Decade (2000-2009). PLoS ONE, 7(9), - . doi:10.1371/journal.pone.0045919
    • Zumla A, Keiser J (2012). Infectious Diseases Clinics of North America -Tropical Diseases volume.
    • Geldmacher C, Hoelscher M, Zumla A (2012). Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Current Opinion in HIV and AIDS, 7(3), 268 - 275. doi:10.1097/COH.0b013e3283524e32
    • Ferrara G, Zumla A, Maeurer M (2012). Intravenous Immunoglobulin (IVIg) for Refractory and Difficult-to-treat Infections. American Journal of Medicine, , - .
    • Ferrara G, Maeurer M, Zumla A (2012). Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections. American Journal of Medicine, 125(10), - . doi:10.1016/j.amjmed.2012.01.023
    • Zumla A (2012). Killer respiratory tract infections: Time to turn the tide. Current Opinion in Pulmonary Medicine, 18(3), 173 - 174. doi:10.1097/MCP.0b013e328351f7d8
    • Rabeeah AA, Memish ZA, Zumla A, Shafi S, McCloskey B, Moolla A, Barbeschi M, Heymann D, Horton R (2012). Mass gatherings medicine and global health security. The Lancet, 380(9836), 3 - 4. doi:10.1016/S0140-6736(12)61110-6
    • Al Rabeeah A, Memish ZA, Zumla A, Shafi S, McCloskey B, Moolla A, Barbeschi M, Heymann D, Horton R (2012). Mass gatherings medicine and global health security.. Lancet, 380(9836), 3 - 4. doi:10.1016/S0140-6736(12)61073-3
    • Fisk M, Peck LF, Miyagi K, Steward MJ, Lee SF, Macrae MB, Morris-Jones S, Zumla AI, Marks DJB (2012). Mycotic aneurysms: A case report, clinical review and novel imaging strategy. QJM, 105(2), 181 - 188.
    • Fisk M, Peck LF, Lee SF, Miyagi K, Steward MJ, Macrae MB, Morris-Jones S, Zumla AI, Marks DJB (2012). Mycotic aneurysms: A case report, clinical review and novel imaging strategy. QJM, 105(2), 181 - 188. doi:10.1093/qjmed/hcq240
    • Bates M, O'Grady J, Mudenda V, Shibemba A, Zumla A (2012). New global estimates of malaria deaths. The Lancet, 380(9841), 560 - 561.
    • Zumla A, Cobelens F (2012). Operational research and MDG tuberculosis control targets. The Lancet Infectious Diseases, 12(4), 262 - 263. doi:10.1016/S1473-3099(12)70034-8
    • Ferrara G, Murray M, Winthrop K, Centis R, Migliori GB, Sotgiu G, Maeurer M, Zumla A (2012). Risk factors associated with pulmonary tuberculosis: Smoking, diabetes and anti-TNFα drugs. Current Opinion in Pulmonary Medicine, 18(3), - . doi:10.1097/MCP.0b013e328351f9d6
    • Kapata N, Chanda-Kapata P, Mwaba P, O'Grady J, Schwank S, Bates M, Zumla A, Grobusch MP, Jansenn S, Mwinga A, Cobelens F (2012). Scale-up of TB and HIV programme collaborative activities in Zambia - a 10-year review. Tropical Medicine and International Health, 17(6), 760 - 766. doi:10.1111/j.1365-3156.2012.02981.x
    • Cummings I, O'Grady J, Zumla A, Pai V, Kolvekar S (2012). Surgery and tuberculosis. Current Opinion in Pulmonary Medicine, 18(3), - . doi:10.1097/MCP.0b013e3283521391
    • Abubakar I, Dara M, Manissero D, Zumla A (2012). Tackling the spread of drug-resistant tuberculosis in Europe. The Lancet, 379(9813), - . doi:10.1016/S0140-6736(11)61428-1
    • Zumla A (2012). The Global Fund Round 11 cancellation fiasco: Turning disaster into opportunity?. International Journal of Tuberculosis and Lung Disease, 16(3), 285 - 286. doi:10.5588/ijtld.12.0066
    • Marks DJ, Fisk MD, Koo CY, Pavlou M, Peck L, Lee SF, Lawrence D, Macrae MB, Wilson AP, Brown JS, Miller RF, Zumla AI (2012). Thoracic empyema: a 12-year study from a UK tertiary cardiothoracic referral centre.. PLoS One, 7(1), e30074 - . doi:10.1371/journal.pone.0030074
    • Zumla A, Behrens RH, Memish ZA (2012). Travel Medicine. Infectious Disease Clinics of North America, 26(3), - . doi:10.1016/j.idc.2012.07.004
    • Abouzeid MS, Zumla AI, Felemban S, Alotaibi B, O'Grady J, Memish ZA (2012). Tuberculosis trends in Saudis and non-Saudis in the Kingdom of Saudi Arabia--a 10 year retrospective study (2000-2009).. PLoS One, 7(6), e39478 - . doi:10.1371/journal.pone.0039478
    • Ferrara G, Zumla A, Maeurer M (2012). Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections.. The American journal of medicine, 125(10), - .

    2011

    • O'Grady J, Maeurer M, Atun R, Abubakar I, Mwaba P, Bates M, Kapata N, Ferrara G, Hoelscher M, Zumla A (2011). Tuberculosis in prisons: anatomy of global neglect.. Eur Respir J, 38(4), 752 - 754. doi:10.1183/09031936.00041211
    • Wrightson JM, Rahman NM, Novak T, Huggett JF, Maskell NA, Zumla A, Miller RF, Davies RJ (2011). Pneumocystis jirovecii in pleural infection: a nucleic acid amplification study.. Thorax, 66(5), 450 - 451. doi:10.1136/thx.2009.129940
    • Caminero JA, Sotgiu G, Zumla A, Migliori GB (2011). Treatment of drug-resistant tuberculosis - Authors' reply.. Lancet Infect Dis, 11(9), 660 - 661. doi:10.1016/S1473-3099(11)70191-8
    • Caminero JA, Sotgiu G, Zumla A, Migliori GB (2011). Treatment of drug-resistant tuberculosis reply. LANCET INFECT DIS, 11(9), 660 - 661.
    • Salvo F, Sadutshang TD, Migliori GB, Zumla A, Cirillo DM (2011). Xpert MTB/RIF test for tuberculosis.. Lancet, 378(9790), 481 - 482. doi:10.1016/S0140-6736(11)61243-9
    • Ferrara G, O'Grady J, Zumla A, Maeurer M (2011). Xpert MTB/RIF test for tuberculosis.. Lancet, 378(9790), 482 - . doi:10.1016/S0140-6736(11)61244-0
    • McNerney R, Ferrara G, O'Grady J, Maeurer M, Zumla A (2011). Screening of immigrants in the UK for latent tuberculosis.. Expert Rev Respir Med, 5(4), 483 - 486. doi:10.1586/ers.11.45
    • Kapata N, Chanda-Kapata P, O'Grady J, Schwank S, Bates M, Mukonka V, Zumla A, Mwaba P (2011). Trends of Zambia's tuberculosis burden over the past two decades.. Trop Med Int Health, 16(11), 1404 - 1409. doi:10.1111/j.1365-3156.2011.02849.x
    • Ferrara G, Parida SK, Zumla A, Richeldi L, Maeurer M (2011). A decade of interferon-γ release assays: quest for the holy grail to diagnose latent infection with mycobacterium tuberculosis?. Am J Respir Crit Care Med, 183(12), 1732 - . doi:10.1164/ajrccm.183.12.1732a
    • O'Grady J, Maeurer M, Mwaba P, Kapata N, Bates M, Hoelscher M, Zumla A (2011). New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis.. Curr Opin Pulm Med, 17(3), 134 - 141. doi:10.1097/MCP.0b013e3283452346
    • Zumla A (2011). Pulmonary infections: 'le terrain est tout, le microbe n'est rien'.. Curr Opin Pulm Med, 17(3), 131 - 133. doi:10.1097/MCP.0b013e328345873a
    • Mwaba P, McNerney R, Grobusch MP, O'Grady J, Bates M, Kapata N, Maeurer M, Zumla A (2011). Achieving STOP TB Partnership goals: perspectives on development of new diagnostics, drugs and vaccines for tuberculosis.. Trop Med Int Health, 16(7), 819 - 827. doi:10.1111/j.1365-3156.2011.02777.x
    • Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A (2011). Immunological biomarkers of tuberculosis.. Nat Rev Immunol, 11(5), 343 - 354. doi:10.1038/nri2960
    • Zumla A, Yew WW (2011). New tools for achieving tuberculosis control: progress and reflexion.. Int J Tuberc Lung Dis, 15(3), 285 - 286.
    • Bomanji J, Almuhaideb A, Zumla A (2011). Combined PET and X-ray computed tomography imaging in pulmonary infections and inflammation.. Curr Opin Pulm Med, 17(3), 197 - 205. doi:10.1097/MCP.0b013e328344db8a
    • O'Grady J, Hoelscher M, Atun R, Bates M, Mwaba P, Kapata N, Ferrara G, Maeurer M, Zumla A (2011). Tuberculosis in prisons in sub-Saharan Africa--the need for improved health services, surveillance and control.. Tuberculosis (Edinb), 91(2), 173 - 178. doi:10.1016/j.tube.2010.12.002
    • Mwaba P, Kapata N, O'Grady J, Bates M, Zumla A, Mcnerney R, Grobusch MP, Maeurer M (2011). Achieving STOP TB Partnership goals: Perspectives on development of new diagnostics, drugs and vaccines for tuberculosis. Tropical Medicine and International Health, 16(7), 819 - 827. doi:10.1111/j.1365-3156.2011.02777.x
    • Bomanji J, Almuhaideb A, Zumla A (2011). Combined PET and X-ray computed tomography imaging in pulmonary infections and inflammation. Current Opinion in Pulmonary Medicine, 17(3), 197 - 205. doi:10.1097/MCP.0b013e328344db8a
    • Zumla A (2011). Editorial introduction. Current Opinion in Pulmonary Medicine, 17(3), - . doi:10.1097/MCP.0b013e32834619c2
    • Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A (2011). Immunological biomarkers of tuberculosis. Nature Reviews Immunology, 11(5), 343 - 354. doi:10.1038/nri2960
    • Abebe M, Kim L, Rook G, Aseffa A, Wassie L, Zewdie M, Zumla A, Engers H, Andersen P, Doherty TM (2011). Modulation of cell death by M. tuberculosis as a strategy for pathogen survival.. Clin Dev Immunol, 2011, 678570 - . doi:10.1155/2011/678570
    • O'Grady J, Bates M, Zumla A, Mwaba P, Kapata N, Maeurer M, Hoelscher M (2011). New and improved diagnostics for detection of drug-resistant pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 17(3), 134 - 141. doi:10.1097/MCP.0b013e3283452346
    • Zumla A (2011). Pulmonary infections: 'Le terrain est tout, le microbe n'est rien'. Current Opinion in Pulmonary Medicine, 17(3), 131 - 133. doi:10.1097/MCP.0b013e328345873a
    • Nunn AJ, Crook AM, Darbyshire JH, Mwaba PB, Chintu C, Ahmed Y, Zumla AI (2011). Essai randomisé placebo contrôlé pour évaluer la réduction de la mortalité et de la morbidité par le cotrimoxazole chez les femmes infectées par le VIH après l'accouchement en Zambie (TOPAZ). Tropical Medicine and International Health, 16(4), 518 - 526. doi:10.1111/j.1365-3156.2011.02731.x
    • Rachow A, Zumla A, Heinrich N, Rojas-Ponce G, Mtafya B, Reither K, Ntinginya EN, O'Grady J, Huggett J, Dheda K, Boehme C, Perkins M, Saathoff E, Hoelscher M (2011). Rapid and accurate detection of Mycobacterium tuberculosis in sputum samples by Cepheid Xpert MTB/RIF assay--a clinical validation study.. PLoS One, 6(6), e20458 - . doi:10.1371/journal.pone.0020458
    • Zumla A (2011). The white plague returns to London--with a vengeance.. Lancet, 377(9759), 10 - 11. doi:10.1016/S0140-6736(10)62176-9
    • Kapata N, Chanda-Kapata P, Mukonka V, Mwaba P, O'Grady J, Schwank S, Bates M, Zumla A (2011). Trends of Zambia's tuberculosis burden over the past two decades. Tropical Medicine and International Health, 16(11), 1404 - 1409. doi:10.1111/j.1365-3156.2011.02849.x
    • O'Grady J, Mwaba P, Bates M, Kapata N, Zumla A (2011). Tuberculosis in prisons in sub-Saharan Africa - a potential time bomb. South African Medical Journal, 101(2), 107 - 108.
    • Abubakar I, Lipman M, Anderson C, Davies P, Zumla A (2011). Tuberculosis in the UK - Time to regain control. BMJ (Online), 343(7818), - . doi:10.1136/bmj.d4281
    • Abubakar I, Lipman M, Anderson C, Davies P, Zumla A (2011). Tuberculosis in the UK--time to regain control.. BMJ, 343, d4281 - .
    • Zumla A, Atun R, Maeurer M, Mwaba P, Ma Z, O'Grady J, Bates M, Dheda K, Hoelscher M, Grange J (2011). Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. TROP MED INT HEALTH, 16(1), 79 - 83. doi:10.1111/j.1365-3156.2010.02665.x
    • Migliori GB, Sotgiu G, Blasi F, Zumla A, Loddenkemper R, Raviglione MC, Abubakar I, Sandgren A, Manissero D (2011). Towards the development of EU/EEA Standards for Tuberculosis Care (ESTC).. Eur Respir J, 38(3), 493 - 495. doi:10.1183/09031936.00094211

    2010

    • Marks DJB, Fisk M, Koo CY, Lee SF, Lawrence D, Miller RF, Zumla A (2010). OUTCOMES FROM SURGICAL MANAGEMENT OF PLEURAL INFECTION: 12-YEAR EXPERIENCE FROM A TERTIARY CARDIOTHORACIC CENTRE. doi:10.1136/thx.2010.150979.18
    • Rodger G, Huggett J, Green C, Zumla A, Morris-Jones S, Yap J (2010). The role of nucleic acid amplification techniques (NAATs) in the diagnosis of infective endocarditis. British Journal of Cardiology, 17(4), 195 - 200.
    • Jarand J, Shean K, O'Donnell M, Loveday M, Kvasnovsky C, Van der Walt M, Adams S, Willcox P, O'Grady J, Zumla A, Dheda K (2010). Extensively drug-resistant tuberculosis (XDR-TB) among health care workers in South Africa.. Trop Med Int Health, 15(10), 1179 - 1184. doi:10.1111/j.1365-3156.2010.02590.x
    • Zumla A, Grange JM (2010). Is the eradication of tuberculosis 'yesterday's ambition' or 'tomorrow's triumph'?. Clin Med, 10(5), 450 - 453.
    • Atun R, Raviglione M, Marais B, Zumla A (2010). Tuberculosis control is crucial to achieve the MDGs.. Lancet, 376(9745), 940 - 941. doi:10.1016/S0140-6736(10)61428-6
    • Caminero JA, Sotgiu G, Zumla A, Migliori GB (2010). Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis.. Lancet Infect Dis, 10(9), 621 - 629. doi:10.1016/S1473-3099(10)70139-0
    • Zumla A, Yew WW, Hui DS (2010). Emerging respiratory infections in the 21st century. Preface.. Infect Dis Clin North Am, 24(3), xiii - xvi. doi:10.1016/j.idc.2010.04.014
    • Dheda K, Warren RM, Zumla A, Grobusch MP (2010). Extensively drug-resistant tuberculosis: epidemiology and management challenges.. Infect Dis Clin North Am, 24(3), 705 - 725. doi:10.1016/j.idc.2010.05.001
    • Zumla AI, Yew W-W, Hui DS (2010). Emerging Respiratory Infections in the 21st Century, an Issue of Infectious Disease Clinics.
    • Dheda K, Badri M, Zumla A (2010). Extensively drug-resistant tuberculosis in South Africa Reply. LANCET, 376(9742), 681 - 682.
    • Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, O'Grady J, Hoelscher M, Zumla A (2010). Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa.. Trop Med Int Health, 15(9), 1052 - 1066. doi:10.1111/j.1365-3156.2010.02581.x
    • Mwaba P, Bates M, Green C, Kapata N, Zumla A (2010). Research capacity strengthening in African countries.. Lancet, 375(9729), 1874 - . doi:10.1016/S0140-6736(10)60874-4
    • Gant V, Vaara M, Makki M, Zumla A, Huggett J (2010). Future diagnosis of sepsis Reply. LANCET, 375(9728), 1780 - 1780.
    • Wallis RS, Pai M, Menzies D, Doherty TM, Walzl G, Perkins MD, Zumla A (2010). Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice.. Lancet, 375(9729), 1920 - 1937. doi:10.1016/S0140-6736(10)60359-5
    • Dheda K, Shean K, Zumla A, Badri M, Streicher EM, Page-Shipp L, Willcox P, John MA, Reubenson G, Govindasamy D, Wong M, Padanilam X, Dziwiecki A, van Helden PD, Siwendu S, Jarand J, Menezes CN, Burns A, Victor T, Warren R, Grobusch MP, van der Walt M, Kvasnovsky C (2010). Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study.. Lancet, 375(9728), 1798 - 1807. doi:10.1016/S0140-6736(10)60492-8
    • Marais BJ, Raviglione MC, Donald PR, Harries AD, Kritski AL, Graham SM, El-Sadr WM, Harrington M, Churchyard G, Mwaba P, Sanne I, Kaufmann SH, Whitty CJ, Atun R, Zumla A (2010). Scale-up of services and research priorities for diagnosis, management, and control of tuberculosis: a call to action.. Lancet, 375(9732), 2179 - 2191. doi:10.1016/S0140-6736(10)60554-5
    • Rakotosamimanana N, Raharimanga V, Andriamandimby SF, Soares JL, Doherty TM, Ratsitorahina M, Ramarokoto H, Zumla A, Huggett J, Rook G, Richard V, Gicquel B, Rasolofo-Razanamparany V, VACSEL/VACSIS Study Group (2010). Variation in gamma interferon responses to different infecting strains of Mycobacterium tuberculosis in acid-fast bacillus smear-positive patients and household contacts in Antananarivo, Madagascar.. Clin Vaccine Immunol, 17(7), 1094 - 1103. doi:10.1128/CVI.00049-10
    • Patel VB, Singh R, Connolly C, Coovadia Y, Peer AK, Parag P, Kasprowicz V, Zumla A, Ndung'u T, Dheda K (2010). Cerebrospinal T-cell responses aid in the diagnosis of tuberculous meningitis in a human immunodeficiency virus- and tuberculosis-endemic population.. Am J Respir Crit Care Med, 182(4), 569 - 577. doi:10.1164/rccm.200912-1931OC
    • Lee SF, Lawrence D, Booth H, Morris-Jones S, Macrae B, Zumla A (2010). Thoracic empyema: current opinions in medical and surgical management.. Curr Opin Pulm Med, 16(3), 194 - 200. doi:10.1097/MCP.0b013e32833883f5
    • Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K (2010). Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments.. Curr Opin Pulm Med, 16(3), 262 - 270. doi:10.1097/MCP.0b013e328337f23a
    • Fears R, Kaufmann S, Ter Meulen V, Zumla A, EASAC Working Group (2010). Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.. Tuberculosis (Edinb), 90(3), 182 - 187. doi:10.1016/j.tube.2010.03.008
    • Grange J, Adhikari M, Ahmed Y, Mwaba P, Dheda K, Hoelscher M, Zumla A (2010). Tuberculosis in association with HIV/AIDS emerges as a major nonobstetric cause of maternal mortality in Sub-Saharan Africa.. Int J Gynaecol Obstet, 108(3), 181 - 183. doi:10.1016/j.ijgo.2009.12.005
    • Marais B, Hoelscher M, Mwaba P, Dheda K, Zumla A (2010). World TB Day 2010: Eradicating tuberculosis in sub-Saharan Africa needs effective and committed north-south partnerships. SAMJ S AFR MED J, 100(3), 153 - 154.
    • Pooran A, Booth H, Miller RF, Scott G, Badri M, Huggett JF, Rook G, Zumla A, Dheda K (2010). Different screening strategies (single or dual) for the diagnosis of suspected latent tuberculosis: a cost effectiveness analysis.. BMC Pulm Med, 10, 7 - . doi:10.1186/1471-2466-10-7
    • Zumla A, Huggett J, Dheda K, Green C, Kapata N, Mwaba P (2010). Trials and tribulations of an African-led research and capacity development programme: the case for EDCTP investments.. Trop Med Int Health, 15(4), 489 - 494. doi:10.1111/j.1365-3156.2010.02479.x
    • Zumla A (2010). The relentless and persistent global threat of a range of pulmonary infections.. Curr Opin Pulm Med, 16(3), 169 - 170. doi:10.1097/MCP.0b013e328337fe68
    • Lenders LM, Meldau R, van Zyl-Smit RN, Woodburne V, Maredza A, Cashmore TJ, Semple PL, Badri M, Zumla A, Dheda K (2010). Comparison of same day versus delayed enumeration of TB-specific T cell responses.. J Infect, 60(5), 344 - 350. doi:10.1016/j.jinf.2010.01.012
    • Ahmed Y, Mwaba P, Grange J, Green C, Zumla A (2010). Community-based interventions to reduce maternal mortality.. Lancet, 375(9713), 457 - 458. doi:10.1016/S0140-6736(10)60189-4
    • Wallis RS, Doherty TM, Zumla A (2010). Biomarkers for tuberculosis disease activity, cure, and relapse Reply. LANCET INFECT DIS, 10(2), 70 - 71.
    • Wallis RS, Wang C, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A (2010). Biomarkers for tuberculosis disease activity, cure, and relapse.. Lancet Infect Dis, 10(2), 68 - 69. doi:10.1016/S1473-3099(10)70003-7
    • Tissari P, Zumla A, Tarkka E, Mero S, Savolainen L, Vaara M, Aittakorpi A, Laakso S, Lindfors M, Piiparinen H, Mäki M, Carder C, Huggett J, Gant V (2010). Accurate and rapid identification of bacterial species from positive blood cultures with a DNA-based microarray platform: an observational study.. Lancet, 375(9710), 224 - 230. doi:10.1016/S0140-6736(09)61569-5
    • Grange J, Mwaba P, Dheda K, Höelscher M, Zumla A (2010). World TB Day 2010--new innovations are required for enhancing the global fight against tuberculosis: the 'captain of all these men of death'.. Trop Med Int Health, 15(3), 274 - 276. doi:10.1111/j.1365-3156.2009.02462.x
    • Dheda K, Badri M, Zumla A (2010). Authors' reply. The Lancet, 376(9742), 681 - 682. doi:10.1016/S0140-6736(10)61329-3
    • Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, Brunet L, van Zyl Smit R, Peter J, Green C, Badri M, Sechi L, Sharma S, Hoelscher M, Dawson R, Whitelaw A, Blackburn J, Pai M, Zumla A (2010). Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples.. PLoS One, 5(3), e9848 - . doi:10.1371/journal.pone.0009848
    • Patel VB, Singh R, Connolly C, Kasprowicz V, Zumla A, Ndungu T, Dheda K (2010). Comparison of a clinical prediction rule and a LAM antigen-detection assay for the rapid diagnosis of TBM in a high HIV prevalence setting.. PLoS One, 5(12), e15664 - . doi:10.1371/journal.pone.0015664
    • Zumla A (2010). Current Opinion in Pulmonary Medicine: Editorial introduction. Current Opinion in Pulmonary Medicine, 16(3), - . doi:10.1097/MCP.0b013e328338c18e
    • Abebe M, Doherty TM, Wassie L, Aseffa A, Bobosha K, Demissie A, Zewdie M, Engers H, Andersen P, Kim L, Huggett J, Rook G, Yamuah LK, Zumla A, VACSEL study group (2010). Expression of apoptosis-related genes in an Ethiopian cohort study correlates with tuberculosis clinical status.. Eur J Immunol, 40(1), 291 - 301. doi:10.1002/eji.200939856
    • Cashmore TJ, Peter JG, van Zyl-Smit RN, Semple PL, Maredza A, Meldau R, Zumla A, Nurse B, Dheda K (2010). Feasibility and diagnostic utility of antigen-specific interferon-gamma responses for rapid immunodiagnosis of tuberculosis using induced sputum.. PLoS One, 5(4), e10389 - . doi:10.1371/journal.pone.0010389
    • Gant V, Zumla A, Huggett J, Vaara M, Makki M (2010). Future diagnosis of sepsis - Authors' reply. The Lancet, 375(9728), 1780 - 1780. doi:10.1016/S0140-6736(10)60803-3
    • van Zyl Smit RN, Pai M, Yew WW, Leung CC, Zumla A, Bateman ED, Dheda K (2010). Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD.. Eur Respir J, 35(1), 27 - 33. doi:10.1183/09031936.00072909
    • Zumla A, Yew W-W, Hui DSC (2010). Preface. Infectious Disease Clinics of North America, 24(3), - . doi:10.1016/j.idc.2010.04.014
    • Sharma OP, Zumla A (2010). David Geraint James Obituary. BRIT MED J, 341, - . doi:10.1136/bmj.c6400

    2009

    • van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Bateman ED, Dheda K (2009). Within-Subject Variability and Boosting of T-Cell IFN-gamma Responses Following Tuberculin Skin Testing. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 179, - .
    • Green C, Huggett J, Zumla A, Hoelscher M (2009). The challenges, value and impact of conducting qPCR in the developing world. European Pharmaceutical Review, (6), 11 - 20.
    • Zumla A, Schaaf HS (2009). Tuberculosis.
    • Witt N, Rodger G, Vandesompele J, Benes V, Zumla A, Rook GA, Huggett JF (2009). An assessment of air as a source of DNA contamination encountered when performing PCR.. J Biomol Tech, 20(5), 236 - 240.
    • Doherty TM, Wallis RS, Zumla A (2009). Biomarkers of disease activity, cure, and relapse in tuberculosis.. Clin Chest Med, 30(4), 783 - x. doi:10.1016/j.ccm.2009.08.008
    • Zumla A, Schaaf HS (2009). Tuberculosis. Preface.. Clin Chest Med, 30(4), xiii - xviii. doi:10.1016/j.ccm.2009.08.020
    • Dheda K, van Zyl-Smit RN, Sechi LA, Badri M, Meldau R, Meldau S, Symons G, Semple PL, Maredza A, Dawson R, Wainwright H, Whitelaw A, Vallie Y, Raubenheimer P, Bateman ED, Zumla A (2009). Utility of quantitative T-cell responses versus unstimulated interferon-{gamma} for the diagnosis of pleural tuberculosis.. Eur Respir J, 34(5), 1118 - 1126. doi:10.1183/09031936.00005309
    • Dheda K, van Zyl-Smit RN, Meldau R, Meldau S, Symons G, Khalfey H, Govender N, Rosu V, Sechi LA, Maredza A, Semple P, Whitelaw A, Wainwright H, Badri M, Dawson R, Bateman ED, Zumla A (2009). Quantitative lung T cell responses aid the rapid diagnosis of pulmonary tuberculosis.. Thorax, 64(10), 847 - 853. doi:10.1136/thx.2009.116376
    • Tissari P, Tarkka E, Mero S, Savolainen L, Vaara M, Zumla A, Huggett J, Carder C, Gant V, Aittakorpi A, Laakso S, Lindfors M, Kumlin N, Piiparinen H, Maeki M (2009). Performance evaluation and further development of PCR and microarray-based Prove-it TM Sepsis assay. INFECTION, 37, 34 - 35.
    • Green C, Huggett JF, Talbot E, Mwaba P, Reither K, Zumla AI (2009). Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods (vol 9, pg 505, 2009). LANCET INFECTIOUS DISEASES, 9(9), 536 - 536.
    • Fears R, Zumla A, ter Meulen V (2009). European bodies can help to tackle TB worldwide.. Nature, 460(7257), 796 - . doi:10.1038/460796c
    • van Zyl-Smit RN, Pai M, Peprah K, Meldau R, Kieck J, Juritz J, Badri M, Zumla A, Sechi LA, Bateman ED, Dheda K (2009). Within-subject variability and boosting of T-cell interferon-gamma responses after tuberculin skin testing.. Am J Respir Crit Care Med, 180(1), 49 - 58. doi:10.1164/rccm.200811-1704OC
    • Gryseels B, Zumla A, Troye-Blomberg M, Kieny MP, Quaglio G, Holtel A, Laang H, Romaris M, De Magistris MT, Nuez AN, Olesen OF, Ghalouci R, Lönnroth A (2009). European Union conference on poverty-related diseases research.. Lancet Infect Dis, 9(6), 334 - 337. doi:10.1016/S1473-3099(09)70129-X
    • Doherty M, Wallis RS, Zumla A, WHO-Tropical Disease Research/European Commission joint expert consultation group (2009). Biomarkers for tuberculosis disease status and diagnosis.. Curr Opin Pulm Med, 15(3), 181 - 187.
    • Zumla A (2009). Editorial: emerging respiratory infections in the 21st century.. Curr Opin Pulm Med, 15(3), 179 - 180. doi:10.1097/MCP.0b013e32832a1dad
    • Schaaf HS, Zumla A (2009). Tuberculosis - comprehensive clinical reference International Edition isbn 97881416039884.
    • Schaaf HS, Zumla A (2009). Tuberculosis -A comprehensive Clinical reference.
    • Huggett J, Green C, Zumla A (2009). Nucleic acid detection and quantification in the developing world.. Biochem Soc Trans, 37(Pt 2), 419 - 423. doi:10.1042/BST0370419
    • Wallis RS, Doherty TM, Onyebujoh P, Vahedi M, Laang H, Olesen O, Parida S, Zumla A (2009). Biomarkers for tuberculosis disease activity, cure, and relapse.. Lancet Infect Dis, 9(3), 162 - 172. doi:10.1016/S1473-3099(09)70042-8
    • Zumla A, Mwaba P, Huggett J, Kapata N, Chanda D, Grange J (2009). Reflections on the white plague.. Lancet Infect Dis, 9(3), 197 - 202. doi:10.1016/S1473-3099(09)70045-3
    • Grange JM, Kapata N, Chanda D, Mwaba P, Zumla A (2009). The biosocial dynamics of tuberculosis.. Trop Med Int Health, 14(2), 124 - 130. doi:10.1111/j.1365-3156.2008.02205.x
    • Dheda K, Van-Zyl Smit RN, Sechi LA, Badri M, Meldau R, Symons G, Khalfey H, Carr I, Maredza A, Dawson R, Wainright H, Whitelaw A, Bateman ED, Zumla A (2009). Clinical diagnostic utility of IP-10 and LAM antigen levels for the diagnosis of tuberculous pleural effusions in a high burden setting.. PLoS One, 4(3), e4689 - . doi:10.1371/journal.pone.0004689
    • Zumla A (2009). Current Opinion in Pulmonary Medicine: Editorial introduction. Current Opinion in Pulmonary Medicine, 15(3), - . doi:10.1097/MCP.0b013e32832a1d8a
    • Cannas A, Calvo L, Girardi E, Kalunga G, Green C, Katemangwe P, Mwaba P, Zumla AI, Huggett JF, Reither K, Maboko L, Hoelscher M, Perkins MD, Talbot EA (2009). Implications of storing urinary DNA from different populations for molecular analyses. PLoS ONE, 4(9), - . doi:10.1371/journal.pone.0006985
    • Cook GC, Zumla A (2009). Manson's tropical diseases.
    • Cook GC, Zumla A (2009). Manson's tropical diseases.
    • Zumla A, Schaaf HS (2009). Preface. Clinics in Chest Medicine, 30(4), - . doi:10.1016/j.ccm.2009.08.020
    • Green C, Huggett JF, Zumla AI, Mwaba P, Talbot E, Reither K (2009). Rapid diagnosis of tuberculosis through the detection of mycobacterial DNA in urine by nucleic acid amplification methods. The Lancet Infectious Diseases, 9(8), 505 - 511. doi:10.1016/S1473-3099(09)70149-5
    • van Zyl-Smit RN, Meldau R, Sechi L, Badri M, Dawson R, Bateman ED, Zumla A, Dheda K (2009). Rapid Imunodiagnosis of Site-Specific Tuberculosis: Is It Useful in Clinical Practice in South Africa?. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 179, - .

    2008

    • Zumla A (2008). Current opinion in pulmonary medicine: Introduction. CURR OPIN PULM MED, 14(3), - .
    • Zumla A (2008). Current opinions on selected respiratory infections causing global morbidity and mortality.. Curr Opin Pulm Med, 14(3), 165 - 167. doi:10.1097/MCP.0b013e3282fb7c99
    • Zumla A (2008). Tuberculosis--the tide can be turned, the battle can be won.. J R Soc Med, 101(3), 100 - 101. doi:10.1258/jrsm.2008.070395
    • Craig GM, Booth H, Hall J, Story A, Hayward A, Goodburn A, Zumla A (2008). Establishing a new service role in tuberculosis care: the tuberculosis link worker. Journal of Advanced Nursing, 61(4), 413 - 424.
    • Von Reyn CF, Zumla AI (2008). BCG vaccination in children. BMJ, 337(7681), 1246 - 1247. doi:10.1136/bmj.a2086
    • von Reyn CF, Zumla AI (2008). BCG vaccination in children.. BMJ (Clinical research ed.), 337, - .
    • Huggett JF, Taylor MS, Kocjan G, Evans HE, Morris-Jones S, Gant V, Novak T, Costello AM, Zumla A, Miller RF (2008). Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax, 63(2), 154 - 159.
    • Huggett JF, Novak T, Garson JA, Green C, Morris-Jones SA, Miller RF, Zumla A (2008). Differential susceptibility of PCR reactions to inhibitors: an important and unrecognised phenomenon.. BMC Research Notes, 1, 70 - 79.
    • Zumla A (2008). Editorial introduction. Current Opinion in Pulmonary Medicine, 14(3), - . doi:10.1097/MCP.0b013e3282ff89fd
    • Wassie L, Demissie A, Aseffa A, Abebe M, Yamuah L, Tilahun H, Petros B, Rook GAW, Zumla A, Andersen A, Doherty TM, VACSIS SG (2008). Ex vivo cytokine mRNA levels correlate with changing clinical status of Ethiopian TB patients and their contacts over time. PLoS ONE, 3, e1522 - .
    • Dheda K, Chan JS, Lala S, Hugget JF, Zumla A, Rook G (2008). Gene expression of IL17 and IL23 in the lungs of patients with active tuberculosis.. Thorax, 63(6), 566 - 568.
    • Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A, UNZA-UCLMS Project LUCOT Collaboration (2008). Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial.. BMJ, 337, a257 - .
    • Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A (2008). Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial.. BMJ (Clinical research ed.), 337, - . doi:10.1136/bmj.a257

    2007

    • Huggett JF, Taylor MS, Kocjan G, Evans HE, Morris-Jones S, Gant V, Novak T, Costello AM, Zumla A, Miller RF (2007). Development of a real time PCR assay for detection of Pneumocystitis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax, , - .
    • Dheda K, Chang J, S H, J F K, L U J, M A Z, A R, G AW (2007). The stability of mRNA encoding IL-4 is increased in pulmonary tuberculosis, while stability of mRNA encoding the antagonistic splice variant, IL-4delta2, is not. Tuberculosis, 87, 237 - 241.
    • Lala S, Dheda K, Chang JS, Huggett JF, Kim LU, Johnson MA, Rook GAW, Keshav S, Zumla A (2007). The pathogen recognition sensor, NOD2, is variably expressed in patients with pulmonary tuberculosis. BMC Infectious Diseases, 7, 96 - .
    • Ciglenecki I, Glynn JR, Mwinga A, Ngwira B, Zumla A, Fine PE, Nunn A (2007). Population differences in death rates in HIV-positive patients with tuberculosis.. Int J Tuberc Lung Dis, 11(10), 1121 - 1128.
    • Mulenga V, Ford D, Walker AS, Mwenya D, Mwansa J, Sinyinza F, Lishimpi K, Nunn A, Gillespie S, Zumla A, Chintu C, Gibb DM, CHAP Trial Team (2007). Effect of cotrimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children.. AIDS, 21(1), 77 - 84. doi:10.1097/QAD.0b013e3280114ed7
    • Craig GM, Booth H, Story A, Hayward A, Hall J, Goodburn A, Zumla A (2007). The impact of social factors on tuberculosis management. Journal of Advanced Nursing, 58(5), 418 - 424. doi:10.1111/j.1365-2648.2007.04257.x
    • Griffiths C, Sturdy P, Brewin P, Bothamley G, Eldridge S, Martineau A, MacDonald M, Ramsay J, Tibrewal S, Levi S, Zumla A, Feder G (2007). Educational outreach to promote screening for tuberculosis in primary care: a cluster randomised controlled trial.. Lancet, 369(9572), 1528 - 1534. doi:10.1016/S0140-6736(07)60707-7
    • Burl S, Hill PC, Jeffries DJ, Holland MJ, Fox A, Lugos MD, Adegbola RA, Rook GA, Zumla A, McAdam KP, Brookes RH (2007). FOXP3 gene expression in a tuberculosis case contact study. Clinical and Experimental Immunology, [Epub ahead of p, - .
    • Huggett J, Miller RF, Taylor M, Costello A, Zumla A (2007). The problems of developing molecular diagnostic tests for opportunistic pathogens: the example of Pneumocystis jirovecii.. J EUKARYOT MICROBIOL, 54(2), 43S - 43S.
    • Dheda K, Pooran A, Pai M, Miller RF, Lesley K, Booth HL, Scott GM, Akbar AN, Zumla A, Rook GA (2007). Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results. Journal of Infection, 55(2), 169 - 173.

    2006

    • Demissie A, Leyten EM, Abebe M, Wassie L, Aseffa A, Abate G, Fletcher H, Owiafe P, Hill PC, Brookes R, Rook G, Zumla A, Arend SM, Klein M, Ottenhoff TH, Andersen PD, T M (2006). Recognition of stage-specific mycobacterial antigens differentiates between acute and latent infections with Mycobacterium tuberculosis. Clinical and Vaccine Immunology, 13(20), 179 - 186.
    • Rook G, Dheda K, Zumla A (2006). Immune systems in developed and developing countries; implications for the design of vaccines that will work where BCG does not. Tuberculosis (Edinb), 86, 152 - 162.
    • Chang JS, Dheda K, Huggett JF, Kim LU, Zumla A, Rook GA (2006). Expression of IL-4 mRNA in peripheral blood mononuclear cells from normal donors in relation to expression of TLR2. Immunology Letters, 106(20), 194 - 197.
    • Kassama Y, Shemko M, Shetty N, Fang Z, Macintire G, Gant V, Zumla A, Goodacre R (2006). An Improved Fluorescent Amplified Fragment Length Polymorphism Method for Typing Mycobacterium tuberculosis. Journal of Clinical Microbiology, 44(1), 288 - 289. doi:10.1128/JCM.44.1.288-289.2006
    • Chang JS, Huggett JF, Dheda K, Kim LU, Zumla A, Rook GA (2006). Myobacterium tuberculosis induces selective up-regulation of TLRs in the mononuclear leukocytes of patients with active pulmonary tuberculosis.. J Immunol, 176(5), 3010 - 3018.
    • Chang J-S, Huggett JF, Dheda K, Kim LU, Zumla A, Rook G (2006). M. tuberculosis induces selective upregulation of Toll-like receptors in the mononuclear leukocytes of patients with active pulmonary tuberculosis. The Journal of Immunology, 176(5), 3010 - 3018.
    • Zumla A, Mullan Z (2006). Turning the tide against tuberculosis.. Lancet, 367(9514), 877 - 878. doi:10.1016/S0140-6736(06)68355-4
    • Perkins MD, Roscigno G, Zumla A (2006). Progress towards improved tuberculosis diagnostics for developing countries.. Lancet, 367(9514), 942 - 943. doi:10.1016/S0140-6736(06)68386-4
    • Demissie A, Wassie L, Abebe M, Aseffa A, Rook G, Zumla A, Andersen P, Doherty TM, VACSEL Study Grp (2006). The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon. INFECT IMMUN, 74(5), 2817 - 2822. doi:10.1128/IAI.75.5.2817-2822.2006
    • Zumla A (2006). Infectious diseases.. Curr Opin Pulm Med, 12(3), 165 - 166. doi:10.1097/01.mcp.0000219263.42686.07
    • Demissie A, Wassie L, Abebe M, Aseffa A, Rook G, Zumla A, Andersen P, Doherty TM (2006). The 6-kilodalton early secreted antigenic target-responsive, asymptomatic contacts of tuberculosis patients express elevated levels of interleukin-4 and reduced levels of gamma interferon. Infection and Immunity, 74(5), 2817 - 2822.
    • Huggett JF, Miller RF, Taylor MS, Costello AM, Zumla A (2006). Problems of Developing Molecular Diagnostic Tests for Opportunistic Pathogens: The Example of Pneumocystis jirovecii. J Eukaryot.Microbiol., 53 Suppl 1, S85 - S86.

    2005

    • Doherty TM, Demissie A, Menzies D, Anderson P, Rook G, Zumla A (2005). Effect of sample handling on analysis of cytokine responses to Mycobacterium tuberculosis in clinical samples using ELISA, ELISPOT and quantitative PCR.. Journal of Microbiological Methods, 298(1-2), 129 - 141.
    • Rook GAW, Dheda K, Zumla A (2005). Do successful tuberculosis vaccines need to be immunoregulatory rather thanmerely Th1-boosting?. Vaccine, 23(17-18), 2115 - 2120. doi:10.1016/j.vaccine.2005.01.069
    • Huggett J, Dheda K, Bustin S, Zumla A (2005). Real-time RT-PCR normalisation; strategies and considerations. Genes and Immunity, 6, 279 - 284.
    • Dheda K, Chang JS, Breen RA, Kim LU, Haddock JA, Huggett JF, Johnson MA, Rook GAW, Zumla A (2005). In vivo and in vitro studies of a novel cytokine, interleukin-4delta2, in pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine, 172(4), 501 - 508. doi:10.1164/rccm.200502-278OC
    • Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GA (2005). Lung remodeling in pulmonary tuberculosis.. J Infect Dis, 192(7), 1201 - 1209. doi:10.1086/444545
    • Dheda K, Chang JS, Breen RA, Haddock JA, Huggett JF, Lipman MC, Johnson MA, Rook GAW, Zumla A (2005). Expression of a novel cytokine, IL-4delta2, in HIV and HIV-tuberculosis co-infection. AIDS, 19(15), 1601 - 1606.
    • Warrens AN, Persey M, Powis SH, Fertleman M, Zumla A (2005). A Guide to the MRCP Part 2 Written Paper.
    • Dheda K, Lalvani A, Miller RF, Scott G, Booth H, Johnson MA, Zumla A, Rook GA (2005). Performance of a T-cell-based diagnostic test for tuberculosis infection in HIV-infected individuals is independent of CD4 cell count. AIDS, 9(17), 2038 - 2041.
    • Lienhardt C, Zumla A (2005). BCG: the story continues. The Lancet, 366(9495), 1414 - 1416. doi:10.1016/S0140-6736(05)67535-6
    • Onyebujoh P, Zumla A, Ribeiro I, Rustomjee R, Mwaba P, Gomes M, Grange JM (2005). Treatment of tuberculosis: present status and future prospects. Bulletin of the World Health Organisation, 83(11), 857 - 865.
    • Zumla A (2005). Towards improving outcomes of fatal pulmonary infections. Current Opinion in Pulmonary Medicine, 11(3), 187 - 188.
    • Dheda K, Huggett JF, Chang JS, Kim LU, Bustin SA, Johnson MA, Rook GAW, Zumla A (2005). The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization. Analytical Biochemistry, 344(1), 141 - 143. doi:10.1016/j.ab.2005.05.022
    • Atadzhanov M, Zumla A, Mwaba P (2005). Study of familial Parkinson's disease in Russia, Uzbekistan, and Zambia. Postgraduate Medical Journal, 81(952), 117 - 121.
    • Dheda K, Booth H, Huggett JF, Johnson MA, Zumla A, Rook GAW (2005). Lung remodelling in tuberculosis. The Journal of Infectious Diseases, 192(7), 1201 - 1210.
    • Lalvani A, Richeldi L, Kunst H, Dheda K, Chang J-S, Kim LU, Huggett JF, Zumla A, Rook GAW, Johnson MA, Pai M, Colford Jr JM, Riley LW (2005). Interferon gamma assays for tuberculosis. Lancet Infectious Diseases, 5(6), 322 - 327. doi:10.1016/S1473-3099(05)70118-3
    • Dheda K, Chang JS, Kim LU, Huggett JF, Johnson MA, Zumla A, Rook GAW (2005). Interferon gamma assays for tuberculosis. The Lancet Infectious Diseases, 5(6), 324 - 325. doi:10.1016/S1473-3099(05)70119-5
    • Rook GAW, Dheda K, Zumla A (2005). Immune responses to TB in developing countries: implications for new vaccines. Nature Reviews Immunology, 5(8), 661 - 667. doi:10.1038/nri1666

    2004

    • Huggett J, Dheda K, Zumla A, Rook G (2004). Crohn's disease and MAP. The Lancet, 364(9452), 2178 - 2178.
    • Dheda K, Huggett JF, Kim LU, Zumla A, Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO (2004). Type 2 cytokines in respiratory syncytial virus bronchiolitis [5] (multiple letters). American Journal of Respiratory and Critical Care Medicine, 169(10), 1167 - 1168.
    • Craig GM, Booth H, Story A, Hall J, Goodburn A, Hayward A, Power R, Zumla A (2004). Preliminary findings from the London TB link project targeting homeless and marginalised groups.
    • Onyebujoh P, Rook GAW, Roscigno G, Rustomjee R, Zumla A (2004). Tuberculosis. Nature Reviews Microbiology, 2(12), 930 - 932.
    • Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Farrelly L, Kaganson N, Zumla A, Gillespie S, Nunn AJ, Gibb DM (2004). Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP):a double-blind randomised placebo-controlled trial. The Lancet, 364(9448), 1865 - 1871. doi:10.1016/S0140-6736(04)17442-4
    • Johnson JL, Nunn AJ, Fourie PB, Ormerod LP, Mugerwa RD, Mwinga A, Chintu C, Ngwira B, Onyebujoh P, Zumla A (2004). Effect of Mycobacterium vaccae (SRL172) immunotherapy on radiographic healing in tuberculosis. International Journal of Tuberculosis and Lung Disease, 8(11), 1348 - 1354.
    • Dheda K, Johnson MA, Zumla A, Rook GA (2004). Smoking is not beneficial for tuberculosis. American Journal of Respiratory and Critical Care Medicine, 170(7), 821 - 821.
    • Fletcher HA, Owiafe P, Jeffries D, Hill P, Rook GA, Zumla A, Doherty TM, Brookes RH Vacsel Study GROUP (2004). Increased expression of mRNA encoding interleukin (IL)-4 and its splice variant IL-4delta2 in cells from contacts of Mycobacterium tuberculosis, in the absence of in vitro stimulation.. Immunology, 112(4), 669 - 673.
    • Tomkins A, Zumla A, Pasvol G, Curtis C, Wright S (2004). Too hard on tropical medicine?. The Lancet, 364(9428), 23 - 23.
    • Dheda K, Rook G, Zumla A (2004). Peripheral T Cell Interferon-{gamma} Responses and Latent Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 170(1), 97 - 98.
    • Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A (2004). Validation of housekeeping genes for normalizing RNA expression in real-time PCR. BioTechniques, 37(1), 112, 116, - 114, 116,.
    • Dheda K, Huggett JF, Bustin SA, Johnson MA, Rook G, Zumla A (2004). Validation of housekeeping genes for normalizing RNA expression in real-time PCR.. Biotechniques, 37(1), 112 - 119.
    • Demissie A, Abebe M, Aseffa A, Rook G, Fletcher H, Zumla A, Weldingh K, Brock I, Andersen P, Doherty TM (2004). Healthy individuals that control a latent infection with Mycobacterium tuberculosis express high levels of Th 1 cytokines and the IL-4 antagonist IL-4delta2. The Journal of Immunology, 172(11), 6938 - 6943.
    • Zumla A (2004). Infectious diseases. Current Opinion in Pulmonary Medicine, 10(3), 157 - 158.
    • Dheda K, Johnson MA, Zumla A, Rook GA, Maier LA (2004). Smoking is not beneficial for tuberculosis (multiple letters). American Journal of Respiratory and Critical Care Medicine, 170(7), 821 - 821.
    • Dheda K, Rook G, Zumla A, Mori T (2004). Peripheral T cell interferon-γ responses and latent tuberculosis [5] (multiple letters). American Journal of Respiratory and Critical Care Medicine, 170(1), 97 - 98.
    • Huggett J, Dheda K, Zumla A, Rook G (2004). edicine 10:157-158. 11. Huggett J, Dheda K, Zumla A, Rook G.. The Lancet, 364, 2178 - 2179.
    • Shapiro HM, Mandy FF, Sandstrom P, De Wit TFR, Jenwitheesuk E, Mwaba P, Nunn AJ, Chintu C, Zumla A, Cassol S (2004). Dried blood spot technology for CD4+ T-cell counting [1] (multiple letters). Lancet, 363(9403), 164 - 165. doi:10.1016/S0140-6736(03)15272-5
    • Huggett J, Dheda K, Zumla A, Rook G, Naser SA, Valentine JF, Gaya DR, MacKenzie JF, Black RA (2004). Crohn's disease and MAP [4] (multiple letters). Lancet, 364(9452), 2178 - 2179. doi:10.1016/S0140-6736(04)17585-5
    • Mwaba P, Cassol S, Nunn AJ, Chintu C, Zumla A (2004). Dried blood spot technology for CD4+T-cell counting - Reply. LANCET, 363(9403), 164 - 165.
    • Dheda K, Huggett JF, Kim LU, Zumla A (2004). Type 2 cytokines in respiratory syncytial virus bronchiolitis. American Journal of Respiratory and Critical Care Medicine, 169(10), 1167 - 1168.
    • Zumla A (2004). Infectious diseases.. Current Opinion in Pulmonary Medicine, 10(3), 157 - 158.
    • Dheda K, Huggett JF, Kim LU, Breen R, Haddock JA, Johnson MA, Zumla A, Rook GAW (2004). IL-4 Delta 2 and Th2 cytokines in human pulmonary tuberculosis.

    2003

    • Zumla A, Fortescue S (2003). BookPower. Postgraduate Medical Journal, 79(938), 670 - 670.
    • Mwaba P, Cassol S, Nunn A, Pilon R, Chintu C, Jane SM, Zumla A (2003). Whole blood versus plasma spots for measurement of HIV-1 viral load in HIV-infected African patients. The Lancet, 362(9401), 2067 - 2068. doi:10.1016/S0140-6736(03)15103-3
    • Mwaba P, Cassol S, Pilon R, Chintu C, Janes M, Nunn A, Zumla A (2003). Use of dried whole blood spots to measure CD4+ lymphocyte counts in HIV-1-infected patients. The Lancet, 362(9394), 1459 - 1460. doi:10.1016/S0140-6736(03)14693-4
    • Ijaz M, Zumla A (2003). Treating AIDS: a new approach. National Review [Online Version], Availa, - .
    • Zumla AI (2003). Editorial overview: Infectious diseases. Current Opinion in Pulmonary Medicine, 9(3), 163 - 165.
    • Huggett JF, McHugh TD, Zumla A (2003). Tuberculosis: amplification-based clinical diagnostic techniques. The International Journal of Biochemistry and Cell Biology, 35(10), 1407 - 1412.
    • Mwaba P, Maboshe M, Chintu C, Squire B, Nyirenda S, Sunkutu R, Zumla A (2003). The relentless spread of tuberculosis in Zambia - trends over the past 37 years (1964-2000). South African Medical Journal, 93(2), 149 - 152.
    • Grange JM, Zumla A (2003). Anti-tuberculosis agents. In Cohen J, Powderly WG (Ed.), Infectious Diseases (pp. 1851 - 1867). : Elsevier Health Sciences.
    • Cook GC, Zumla A (2003). Cutaneous Viral Disease. In Cook GC, Zumla AI (Ed.), Manson's Tropical Diseases (pp. 841 - 859). : W.B. Saunders, Elsevier Science Ltd.
    • Zumla A, Gandy M (2003). Epilogue: Politics, science and the 'new' tuberculosis. In Gandy M, Zumla A (Ed.), The return of the white plague: global poverty and the 'new' tuberculosis (pp. 237 - 241). : .
    • Maartens G, Mwaga P, Zumla A (2003). General Approach to the Patient. In Cook GC (Ed.), Manson's Tropical Diseases (pp. 95 - 109). : W.B. Saunders, Elsevier Science Ltd.
    • Grange JM, Zumla A (2003). Human Disease due to Environmental Mycobacteria. In Cook GC (Ed.), Manson's Tropical Diseases (pp. 1053 - 1064). : W.B. Saunders, Elsevier Science Ltd.
    • Zumla A, Sa'adu A, Roitt I (2003). Immunological Aspects of Tropical Diseases. In Cook GC, Zumla AI (Ed.), Manson's Tropical Diseases (pp. 57 - 73). : W.B. Saunders, Elsevier Science Ltd.
    • Zumla AI (2003). Infectious diseases. Current Opinion in Pulmonary Medicine, 9(3), 163 - 165. doi:10.1097/00063198-200305000-00001
    • Gandy M, Zumla A (2003). Introduction. In Gandy M, Zumla A (Ed.), The return of the white plague: global poverty and the 'new' tuberculosis (pp. 7 - 12). : Verso.
    • Manson SP, Cook GC, Zumla A (2003). Manson's tropical diseases.
    • Manson SP, Cook GC, Zumla A (2003). Manson's tropical diseases.
    • Gandy M, Zumla A (2003). The Return of the White Plague: Global Poverty and the 'New' Tuberculosis.
    • Grange JM, Zumla A (2003). Tuberculosis. In Cook GC (Ed.), Manson's Tropical Diseases (pp. 995 - 1052). : W.B. Saunders, Elsevier Science Ltd.
    • Harries AD, Hargreaves NJ, Zumla A (2003). Tuberculosis and HIV infection in sub-Saharan Africa. In Gandy M, Zumla A (Ed.), The return of the white plague: global poverty and the 'new' tuberculosis (pp. 112 - 124). : Verso.

    2002

    • Zumla A (2002). Betrayal of trust. Journal of the Royal Society of Medicine, 95(6), 319 - 320.
    • Zumla A (2002). Drugs for neglected diseases. The Lancet Infectious Diseases, 2(7), 393 - .
    • Donaldson IJ, Shefta J, Lawson CA, Bushnell JR, Morgan AW, Isaacs JD, Carpenter D, Shaw M-A, Rooth I, Quinnell RJ, Zumla AM, Ollier WE, Chintu CZ, Muyinda GP, Hill AV, Boylston AW (2002). Unique TCR β-subunit variable gene haplotypes in Africans. Immunogenetics, 53(10-11), 884 - 893. doi:10.1007/s00251-001-0406-8
    • Gandy M, Zumla A (2002). Theorizing tuberculosis: a reply to Porter and Ogden. Social Science and Medicine, 55(5), 399 - 401.
    • Bodman-Smith MD, Williams I, Johnstone R, Boylston A, Lydyard PM, Zumla A (2002). T cell receptor usage in patients with non-progressing HIV infection. Clinical and Experimental Immunology, 130, 115 - 120.
    • Kasolo F, Lishimpi K, Chintu C, Mwaba P, Mudenda V, Maswahu D, Terunuma H, Fletcher H, Nunn A, Lucas S, Zumla A (2002). Identification of Pneumocystis carinii DNA by polymerase chain reaction in necropsy lung samples from children dying of respiratory tract illnesses. The Journal of Pediatrics, 140(3), 367 - 369.
    • Lishimpi K, Kasolo F, Chintu C, Mwaba P, Mudenda V, Maswahu D, Terunuma H, Fletcher H, Nunn A, Lucas S, Zumla A (2002). Identification of Pneumocystis carinii DNA in oropharyngeal mouth washes from AIDS children dying of respiratory illnesses. AIDS, 16(6), 932 - 934.
    • Zumla A, Grange J (2002). Infection and disease caused by environmental mycobacteria. Current Opinion in Pulmonary Medicine, 8(3), 166 - 172.
    • Zumla A (2002). Editorial overview: infectious diseases. Current Opinion in Pulmonary Medicine, 8(3), 151 - 153.
    • ZUMLA A (2002). Tropical Lung Diseases CLINICS IN CHEST MEDICINE.
    • Gandy M, Zumla A (2002). The resurgence of disease: social and historical perspectives on the 'new' tuberculosis. Social Science and Medicine, 55(3), 385 - 396.
    • Kafwabulula M, Ahmed K, Nagatake T, Gotoh J, Mitarai S, Oizumi K, Zumla A (2002). Evaluation of PCR-based methods for the diagnosis of tuberculosis by identification of mycobacterial DNA in urine samples.. Int J Tuberc Lung Dis, 6(8), 732 - 737.
    • Kafwabulula M, Ahmed K, Nagatake T, Gotoh J, Mitarai S, Terunuma H, Zumla A (2002). Evaluation of PCR-based methods for the diagnosis of tuberculosis by identification of mycobacterial DNA in urine samples. International Journal of Tuberculosis and Lung Disease, 6(8), 1 - 6.
    • Chintu C, Mudenda V, Lucas S, Nunn A, Lishimpi K, Maswahu D, Kasolo F, Mwaba P, Bhat G, Terunuma H (2002). Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. The Lancet, 360(9338), 985 - 990. doi:10.1016/S0140-6736(02)11082-8
    • Mwinga A, Nunn A, Ngwira B, Chintu C, Warndorff D, Fine P, Darbyshire J, Zumla A (2002). Randomized placebo-controlled clinical trial of Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis.. The Lancet, 360(9339), 1050 - 1055. doi:10.1016/S0140-6736(02)11141-X
    • Zumla A, Costello A (2002). Ethics of healthcare research in developing countries. Journal of the Royal Society of Medicine, 95(6), 275 - 276.
    • Zumla AI, James DG (2002). Immunologic aspects of tropical lung disease. Clinics in Chest Medicine, 23(2), 283 - 308.
    • Zumla AI, Grange J (2002). Non-tuberculous mycobacterial pulmonary infections. Clinics in Chest Medicine, 23(2), 369 - 376.
    • Grange JM, Zumla A (2002). The global emergency of tuberculosis: what is the cause?. Journal of the Royal Society of Health, 122(2), 78 - 81.
    • Sharma OP, Zumla AI (2002). Tropical lung disease. Clinics in Chest Medicine, 23(2), xv - xvii.

    2001

    • Zumla A (2001). Infectious diseases. Current Opinion in Pulmonary Medicine, 7(3), 113 - 115.
    • Zumla A (2001). Infectious diseases - editorial overview. Current Opinion in Pulmonary Medicine, 7(3), 113 - 115.
    • Zumla A, Grange J (2001). Multidrug-resistant tuberculosis - can the tide be turned?. The Lancet Infectious Diseases, 1(3), 199 - 202.
    • Lishimpi K, Chintu C, Lucas S, Mudenda V, Kaluwaji J, Story A, Maswahu D, Bhat G, Nunn AJ, Zumla A (2001). Necropsies in African children: consent dilemmas for parents and guardians. Archives of Disease in Childhood, 84(6), 463 - 467.
    • Grange J, Story A, Zumla A (2001). Tuberculosis in disadvantaged groups. Current Opinion in Pulmonary Medicine, 7(3), 160 - 164.
    • Mwaba P, Mwansa J, Chintu C, Pobee J, Scarborough M, Portsmouth S, Zumla A (2001). Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgraduate Medical Journal, 77(914), 769 - 773.
    • Rook GA, Zumla A (2001). Advances in the immunopathogenesis of pulmonary tuberculosis. Current Opinion in Pulmonary Medicine, 7(3), 116 - 123.
    • Grange JM, Gandy M, Farmer P, Zumla A (2001). Historical declines in tuberculosis: nature, nurture and the biosocial model. International Journal of Tuberculosis and Lung Disease, 5(3), 208 - 212.
    • Balakrishnan I, Zumla A (2001). African trypanosomiasis. In Gillespie SH, Pearson RD (Ed.), Principles and practice of clinical parasitology (pp. - ). : John Wiley & Sons, Inc.

    2000

    • Zumla A (2000). Infectious diseases. Current Opinion in Pulmonary Medicine, 6(3), 171 - 173.
    • Zumla A, Malon P, Henderson J, Grange JM (2000). Impact of HIV infection on tuberculosis. Postgraduate Medical Journal, 76(895), 259 - 268.
    • Tshibwabwa ET, Mwaba P, Bogle-Taylor J, Zumla A (2000). Four-year study of abdominal ultrasound in 900 Central African adults with AIDS referred for diagnostic imaging. Abdominal Imaging, 25(3), 290 - 296.
    • Grange JM, Zumla A (2000). Advances in the management of tuberculosis: clinical trials and beyond. Current Opinion in Pulmonary Medicine, 6(3), 193 - 197.
    • Baker RW, Walker BR, Shaw RJ, Honour JW, Jessop DS, Lightman SL, Zumla A, Rook GA (2000). Increased cortisol: cortisone ratio in acute pulmonary tuberculosis.. Am J Respir Crit Care Med, 162(5), 1641 - 1647. doi:10.1164/ajrccm.162.5.9912119
    • Baker RW, Walker BR, Shaw RJ, Honour JW, Jessop DS, Lightman SL, Zumla A, Rook GA (2000). Increased cortisol: cortisone ratio in acute pulmonary tuberculosis. American Journal of Respiratory and Critical Care Medicine, 162(5), 1641 - 1647.
    • Goldsack NR, Allen S, Chiu C, Dart S, Zumla A, Johnson MA, Lipman MCI (2000). The changing incidence of mycobacterial infections in an HIV plus VE population.. THORAX, 55, A82 - A82.
    • Waddell RD, Chintu C, Lein AD, Zumla A, Karagas MR, Baboo KS, Habbema JD, Tosteson AN, Morin P, Tvaroha S, Arbeit RD, Mwinga A, von Reyn CF (2000). Safety and immunogenicity of a five-dose series of inactivated Mycobacterium vaccae vaccination for the prevention of HIV-associated tuberculosis. Clinical Infectious Diseases, 30(Supple), S309 - S315.
    • Taylor WR, Zumla A (2000). Referral times of Vietnamese refugees with tuberculosis in camps in Hong Kong. International Journal of Tuberculosis and Lung Disease, 4(4), 350 - 355.
    • Rook G, Baker R, Walker B, Honour J, Jessop D, Hernandez-Pando R, Arriaga K, Shaw R, Zumla A, Lightman S (2000). Local regulation of glucocorticoid activity in sites of inflammation. Insights from the study of tuberculosis. Annals of the New York Academy of Sciences, 917, 913 - 922.
    • Costello A, Zumla A (2000). Moving to research partnerships in developing countries. BMJ (Clinical Research Ed.), 321(7264), 827 - 829.
    • Craddock TP, Zumla AM, Ollier WE, Chintu CZ, Muyinda GP, Lancaster FC, Boylston AW (2000). Predominance of one T-cell antigen receptor BV haplotype in African populations. Immunogenetics, 51(3), 231 - 237.

    1999

    • Zumla A, Squire SB, Chintu C, Grange JM (1999). The tuberculosis pandemic: implications for health in the tropics: a reply. T ROY SOC TROP MED H, 93(6), 678 - 679.
    • Day JH, Williams IG, Zumla A, Miller RF (1999). Protection from Pneumocystis carinii pneumonia. Sexually Transmitted Infections, 75(3), 202 - 203.
    • Zumla A, Grange JM (1999). Doing something about tuberculosis.. BMJ, 318(7189), 956 - .
    • Waddell RD, von Reyn CF, Baboo KS, Mwinga A, Chintu C, Zumla A (1999). The effects of BCG immunization and human immunodeficiency virus infection on dual skin test reactions to purified protein derivative and Mycobacterium avium sensitin among adults in Zambia.. Int J Tuberc Lung Dis, 3(3), 255 - 260.
    • Zumla A, Squire SB, Chintu C, Grange JM (1999). The tuberculosis pandemic: implications for health in the tropics.. Trans R Soc Trop Med Hyg, 93(2), 113 - 117.
    • Zumla A, Mwaba P, Squire SB, Grange JM (1999). The tuberculosis pandemic--which way now?. J Infect, 38(2), 74 - 79.
    • Grange J, Zumla A (1999). Tuberculosis and the poverty-disease cycle [editorial]. Journal of the Royal Society of Medicine, 92(3), 105 - 107.
    • Ahmed Y, Mwaba P, Chintu C, Grange JM, Ustianowski A, Zumla A (1999). A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. International Journal of Tuberculosis and Lung Disease, 3(8), 675 - 680.
    • Baboo KS, Luo NP, Murphy JR, Cummings C, Chintu C, Ustianowski A, DuPont HL, Kelinowski M, Mathewson JJ, Zumla A (1999). HIV-1 seroprevalence in Zambian patients with acute diarrhea: a community-based study. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 20(2), 160 - 163.
    • Grange JM, Zumla A (1999). Paradox of the global emergency of tuberculosis. The Lancet, 353(9157), 996 - 996.
    • James DG, Zumla A (1999). The granulomatous disorders.
    • Zumla A, Squire SB, Chintu C, Grange JM (1999). The tuberculosis pandemic: Implications for health in the tropics. International Journal of Leprosy and Other Mycobacterial Diseases, 67(4 SUPPL.), 529 - 530.
    • Harries AD, Zumla A, Bertel Squire S, Chintu C, Grange JM (1999). The tuberculosis pandemic: Implications for health in the tropics (multiple letters) [1]. Transactions of the Royal Society of Tropical Medicine and Hygiene, 93(6), 678 - 679.
    • Grange J, Zumla A (1999). Tuberculosis and the poverty-disease cycle.. J R Soc Med, 92(3), 105 - 107.

    1998

    • Rook GA, Zumla A (1998). Is the Gulf War syndrome an immunologically mediated phenomenon?. Hosp Med, 59(1), 10 - 11.
    • Rook GA, Zumla A (1998). Is the Gulf War syndrome an immunologically mediated phenomenon? [editorial]. Hospital Medicine, 59(1), 10 - 11.
    • Luo N, Perera C, Holton J, Ayles H, Zumla A (1998). Spread of Neisseria meningitidis group A clone III-I meningitis epidemic into Zambia. Journal of Infection, 36(2), 141 - 143.
    • Luo N, Perera C, Holton J, Ayles H, Zumla A (1998). Spread of Neisseria meningitidis group A clone III-I meningitis epidemic into Zambia. J INFECT, 36(2), 141 - 143.
    • Baker R, Zumla A (1998). The cutaneous manifestations of mycobacterial diseases. Clinical Microbiology and Infection, 4(8), 460 - 463.
    • Zumla A, Grange J (1998). Tuberculosis. BMJ, 316(7149), 1962 - 1964.
    • Ustianowski AP, Zumla A (1998). Hydatid disease.. Clin Microbiol Infect, 4(7), 405 - 409.
    • Zumla A, Grange J (1998). Science, medicine, and the future - Tuberculosis. BRIT MED J, 316(7149), 1962 - 1964.
    • Zumla A, Grange JM (1998). Establishing a united front against the injustice of tuberculosis.. Int J Tuberc Lung Dis, 2(3), 179 - 181.
    • Zumla A, Grange JM (1998). Establishing a united front against the injustice of tuberculosis [editorial]. INT J TUBERC LUNG DIS, 2(3), 179 - 181.
    • Zumla A, Grange J (1998). Galloping consumption. NURS TIMES, 94(14), 14 - 14.
    • Chintu C, Dupont HL, Kaile T, Mahmoud M, Marani S, Baboo KS, Mwansa W, Sakala K, Sunkutu R, Zumla A (1998). Human immunodeficiency virus-associated diarrhea and wasting in Zambia: selected risk factors and clinical associations. AM J TROP MED HYG, 59(1), 38 - 41.

    1997

    • Grange JM, Zumla A (1997). Making DOTS succeed. Directly Observed Treatment, Short Course.. Lancet, 350(9072), 157 - .
    • Grange J, Zumla A (1997). Tuberculosis--an epidemic of injustice. , 31(6), 637 - 639.
    • (1997). AIDS and Respiratory Medicine.
    • Zumla A, Johnson M, Miller R (1997). AIDS and respiratory medicine.
    • Baker R, Shaw RJ, Rook GAW, Honour J, Lightman SL, Walker BR, Zumla A (1997). Are there subtle abnormalities of glucocorticoid metabolism in active pulmonary tuberculosis which affect immune responses?.
    • Baker R, Shaw RJ, Rook GAW, Honour J, Lightman SL, Walker BR, Zumla A (1997). Glucocorticoids and Acute Pulmonary Tuberculosis: a clue to pathogenesis?.
    • Rook GA, Zumla A (1997). Gulf War syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile?. The Lancet, 349(9068), 1831 - 1833.
    • Zumla A, Rowland-Jones S, McMichael A (1997). Lung immunology in AIDS patients. In Zumla A, Miller R, Johnson M (Ed.), AIDS and Respiratory Medicine (pp. 15 - 40). : Chapman & Hall.
    • Grange JM, Zumla A (1997). Making DOTS succeed. The Lancet, 350(9072), 157 - 157. doi:10.1016/S0140-6736(05)62344-6
    • DeCock KM, Miller R, Zumla A, Holton J, Williams I (1997). Noscomial transmission of tuberculosis in HIV/AIDS units in London. Genitourinary Medicine, 73(4), 322 - 322. doi:10.1136/sti.73.4.322
    • De Cock KM, Miller ROB, Zumla A, Holton J, Williams IAN (1997). Nosocomial transmission of tuberculosis in HIV/AIDS units in London. Sexually Transmitted Infections, 73(4), 322 - 322. doi:10.1136/sti.73.4.322
    • Chintu C, Zumla A (1997). Paediatric TB and the Human Immunodeficiency Virus Epidemic. In Zumla A, Johnson M, Miller R (Ed.), AIDS and Respiratory Medicine (pp. 345 - 350). : Chapman & Hall.
    • Baker R, Shaw RJ, Rook GAW, Honour J, Lightman SL, Walker BR, Zumla A (1997). Patients with acute pulmonary tuberculosis (Tb) have subtle abnormalities of glucocorticoid metabolism which may affect immune responses.
    • Baker R, Shaw RJ, Rook GAW, Honour J, Lightman SL, Walker BR, Zumla A (1997). Patients with acute pulmonary tuberculosis (Tb) have subtle but crucial abnormalities of steroid metabolism which may persist after cure or be constitutive.
    • Tshibwabwa-Tumba E, Mwinga A, Pobee JOM, Zumla A (1997). Radiological features of pulmonary tuberculosis in 963 HIV-infected adults at three Central African Hospitals. Brain and Language, 52(11), 837 - 841.
    • Tshibwabwa-Tumba E, Mwinga A, Pobee JOM, Zumla A (1997). Radiological features of pulmonary tuberculosis in 963 HIV-infected adults in three Central African Hospitals. Clinical Radiology, (52), 837 - 841.
    • Zumla A, Miller RF (1997). Sinusitis and sinus disease. In Zumla A, Johnson MA, Miller RF (Ed.), AIDS and Respiratory Medicine (pp. 345 - 350). : Chapman & Hall.
    • ZUMLA A (1997). Sinusitis and sinus disease in HIV infection. In Zumla A, Miller RF (Ed.), Aids and Respiratory Medicine (pp. 153 - 162). : .
    • Luo NP, Perera CU, Holton JM, Ayles H, Zumla A (1997). Spread of neisseria meningitidis group A, Clone III-I meningitis into Zambia. A two year prospective study. Journal of Infection, , - .
    • Rook GAW, Baker R, Zumla A (1997). Steroid metabolism and immunity: therapeutic implications. BioDrugs, 8(3), 157 - 163.
    • Grange J, Zumla A (1997). Tuberculosis: an epidemic of injustice. Journal of the Royal College of Physicians of London, 31(6), 637 - 639.
    • Baker R, Rook GA, Zumla A (1997). Adrenal function and the hypothalamo-pituitary adrenal axis in immunodeficiency virus-associated tuberculosis. International Journal of Tuberculosis and Lung Disease, 1(3), 289 - 291.

    1996

    • Rose S, Paul T, Lancaster F, Zumla A, Munyinda G, Chuntu B, Boylston A (1996). TCR beta V allelic frequencies in Africans and Caucasians. HUM IMMUNOL, 47(1-2), P593 - P593.
    • Matondo P, Zumla A (1996). The spectrum of African Kaposi's sarcoma: is it consequential upon diverse immunological responses?. Scand J Infect Dis, 28(3), 225 - 230.
    • Baker RW, Zumla A, Rook GAW (1996). Tuberculosis, steroid metabolism and immunity. QJM-INT J MED, 89(5), 387 - 394.
    • Luo NP, Baboo KS, Mwenya D, Diab A, Perera CU, Cummings C, Dupont HL, Murphy JR, Zumla A (1996). Isolation of Campylobacter species from Zambian patients with acute diarrhoea.. East Afr Med J, 73(6), 395 - 396.
    • Zumla A, James DG (1996). Granulomatous infections: etiology and classification.. Clin Infect Dis, 23(1), 146 - 158.

    1995

    • Chintu C, Luo C, Bhat G, DuPont HL, Mwansa-Salamu P, Kabika M, Zumla A (1995). Impact of the human immunodeficiency virus type-1 on common pediatric illnesses in Zambia.. J Trop Pediatr, 41(6), 348 - 353.
    • Patil P, Elem B, Zumla A (1995). Pattern of adult malignancies in Zambia (1980-1989) in light of the human immunodeficiency virus type 1 epidemic.. J Trop Med Hyg, 98(4), 281 - 284.
    • Mathewson JJ, Jiang ZD, Zumla A, Chintu C, Luo N, Calamari SR, Genta RM, Steephen A, Schwartz P, DuPont HL (1995). HEp-2 cell-adherent Escherichia coli in patients with human immunodeficiency virus-associated diarrhea.. J Infect Dis, 171(6), 1636 - 1639.
    • Luo N, Kasolo F, Ngwenya BK, du Pont HL, Zumla A (1995). Use of saliva as an alternative to serum for HIV screening in Africa.. S Afr Med J, 85(3), 156 - 157.
    • Zumla A, Chintu C (1995). Parasites and HIV-related diarrhoea.. S Afr Med J, 85(6), 494 - 495.
    • STEEPHEN A, RAIJMAN I, SCHWARZ P, ELZIMALTY H, MALATY HM, SELLIN J, DUPONT HB, ZUMLA A, GENTA R (1995). THE SPECTRUM OF GASTRITIS IN ZAMBIAN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME. GASTROENTEROLOGY, 108(4), A921 - A921.
    • Chintu C, Zumla A (1995). Childhood tuberculosis and infection with the human immunodeficiency virus.. J R Coll Physicians Lond, 29(2), 92 - 95.
    • Chintu C, Luo C, Baboo S, Khumalo-Ngwenya B, Mathewson J, DuPont HL, Zumla A (1995). Intestinal parasites in HIV-seropositive Zambian children with diarrhoea.. J Trop Pediatr, 41(3), 149 - 152.

    1994

    • Gupta K, Carmichael P, Zumla A (1994). 100 Short Cases for the MRCP.
    • Khumalo-Ngwenya B, Luo NP, Chintu C, Sunkutu R, Sakala-Kazembe F, Baboo KS, Mathewson J, Zumla A (1994). Gut parasites in HIV-seropositive Zambian adults with diarrhoea.. East Afr Med J, 71(6), 379 - 383.
    • Zumla A, Chintu C, Luo C (1994). Common childhood illnesses and HIV infection in Africa.. S Afr Med J, 84(5), 296 - 298.
    • Zumla A, Chintu C (1994). Tuberculosis and HIV infection.. Lancet, 343(8901), 851 - 852.
    • Warrens AN (1994). A Guide to the Mrcp Part 2 Written Paper / Anthony N. Warrens ... Et Al. ; With Additional Material from Shaun McGee, R. Campbell Tait.
    • STEEPHEN A, SCHWARZ P, ZUMLA A, CHINTU C, MATHEWSON J, DUPONT H, CALAMARI S, GENTA R, SELLIN J (1994). COLONIC ENTEROADHERENT BACTERIA (EAB) IN AIDS PATIENTS WITH CHRONIC DIARRHEA AND WASTING IN ZAMBIA - CORRELATION OF CLINICAL, ENDOSCOPIC AND PATHOLOGICAL FINDINGS. GASTROENTEROLOGY, 106(4), A777 - A777.
    • Luo C, Chintu C, Bhat G, Raviglione M, Diwan V, DuPont HL, Zumla A (1994). Human immunodeficiency virus type-1 infection in Zambian children with tuberculosis: changing seroprevalence and evaluation of a thioacetazone-free regimen.. Tuber Lung Dis, 75(2), 110 - 115.
    • Mathewson JJ, Jiang ZD, DuPont HL, Chintu C, Luo N, Zumla A (1994). Intestinal secretory IgA immune response against human immunodeficiency virus among infected patients with acute and chronic diarrhea.. J Infect Dis, 169(3), 614 - 617.
    • Oshitani H, Kasolo FC, Mpabalwani M, Luo NP, Matsubayashi N, Bhat GH, Suzuki H, Numazaki Y, Zumla A, DuPont HL (1994). Association of rotavirus and human immunodeficiency virus infection in children hospitalized with acute diarrhea, Lusaka, Zambia.. J Infect Dis, 169(4), 897 - 900.

    1993

    • Chintu C, Luo C, Bhat G, Raviglione M, DuPont H, Zumla A (1993). Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I.. Arch Dis Child, 68(5), 665 - 668.
    • Zumla A, Carmichael P, Bogaerde JVD (1993). MCQs for the MRCP.
    • Chintu C, Bhat G, Luo C, Raviglione M, Diwan V, Dupont HL, Zumla A (1993). Seroprevalence of human immunodeficiency virus type 1 infection in Zambian children with tuberculosis.. Pediatr Infect Dis J, 12(6), 499 - 504.
    • Chintu C, Zumla A (1993). AIDS case definitions in developing countries.. Lancet, 342(8878), 1054 - 1055.
    • Giangaspero M, Vacirca G, Morgan D, Baboo KS, Luo NP, DuPont HL, Zumla A (1993). Anti-bovine viral diarrhoea virus antibodies in adult Zambian patients infected with the human immunodeficiency virus.. Int J STD AIDS, 4(5), 300 - 302.
    • Chintu C, Malek A, Nyumbu M, Luo C, Masona J, DuPont HL, Zumla A (1993). Case definitions for paediatric AIDS: the Zambian experience.. Int J STD AIDS, 4(2), 83 - 85.

    1992

    • Zumla A, van den Bogaerde J (1992). Superantigens--progress in understanding microbial pathogenesis.. S Afr Med J, 82(3), 146 - 148.
    • Zumla A (1992). Superantigens, T cells, and microbes.. Clin Infect Dis, 15(2), 313 - 320.
    • Zumla A, Marguerie C, So A, Yokoyama WM, Saito T, Batchelor JR, Lechler RI (1992). Co-expression of human T cell receptor chains with mouse CD3 on the cell surface of a mouse T cell hybridoma.. J Immunol Methods, 149(1), 69 - 76.
    • Zumla A, McCormack A, George A, Batchelor R, Lechler R (1992). Use of a murine T-cell hybridoma expressing human T-cell receptor alpha- and beta-gene products as a tool for the production of human T-cell receptor-specific monoclonal antibodies.. Hum Immunol, 35(3), 141 - 148.
    • Zumla A, Croft SL (1992). Chemotherapy and immunity in opportunistic parasitic infections in AIDS.. Parasitology, 105 Suppl, S93 - 101.
    • Zumla A, Croft SL (1992). Chemotherapy and immunity in opportunistic parasitic infections in AIDS.. Parasitology, 105 Suppl, - .
    • Zumla A (1992). Chloroquine and proguanil prophylaxis in travellers to Kenya.. Lancet, 339(8784), 62 - 63.

    1991

    • ZUMLA A (1991). MANAGEMENT AND MICROBIOLOGY OF BITES AND BURNS. CURR OPIN INFECT DIS, 4(5), 639 - 648.
    • Zumla A, Mathur M, Stewart J, Wilkinson L, Isenberg D (1991). T cell receptor expression in Sjögren's syndrome.. Ann Rheum Dis, 50(10), 691 - 693.
    • Zumla A (1991). Mimics of sarcoidosis. Leprosy.. Sarcoidosis, 8(2), 89 - 94.
    • ZUMLA A, James DG (1991). Lung Immunology in the Tropics. Chapter 1,. In LeEnfant C, Sharma O (Ed.), Lung Disease in the Tropics. (pp. - ). : .
    • Zumla A, Williams W, Mudd D, Locniskar M, Behrens R, Isenberg D, McAdam KP (1991). Expression of a common idiotype PR4 in the sera of patients with leprosy.. Clin Exp Immunol, 84(3), 522 - 526.
    • Zumla A, Savva D, Wheeler RB, Hira SK, Luo NP, Kaleebu P, Sempala SK, Johnson JD, Holliman R (1991). Toxoplasma serology in Zambian and Ugandan patients infected with the human immunodeficiency virus.. Trans R Soc Trop Med Hyg, 85(2), 227 - 229.
    • Luo NP, Perera CU, Zumla A (1991). Salmonella septic arthritis.. J Infect, 23(1), 101 - .

    1990

    • PERERA CU, LUO NP, ZUMLA A (1990). BACTEREMIAS IN HIV-POSITIVE PATIENTS. LANCET, 336(8719), 877 - 878.
    • Zumla A (1990). Autoantibodies and tropical infections.. Trans R Soc Trop Med Hyg, 84(1), 162 - 165.
    • ZUMLA A, KHAN MI (1990). HEALTH MIRACLES IN THE HOLY-KORAN. SAUDI MED J, 11(3), 253 - 253.
    • Zumla A, Luo NP (1990). Surgery and Salmonella.. BMJ, 300(6735), 1342 - .

    1989

    • Zumla A, Laurenson I (1989). Malaria prophylaxis--a persisting dilemma.. J Antimicrob Chemother, 23(5), 809 - 810.
    • Zumla A (1989). Topical zoonosis.. J Infect, 19(3), 291 - .
    • ZUMLA A (1989). EMERGENCE OF LEISHMANIASIS IN THE WAKE OF AIDS. S AFR MED J, 76(6), 285 - 285.
    • Zumla A (1989). Dysgonic fermenter type 2 infection.. Lancet, 2(8663), 627 - .
    • Zumla A, Lipscomb G (1989). Purpura and sepsis--rarer causes?. Br J Dermatol, 120(5), 715 - 716.
    • Zumla A, James GD (1989). Sarcoidosis and leprosy--an epidemiological, clinical, pathological and immunological comparison.. Sarcoidosis, 6(2), 88 - 96.
    • Zumla A, Lulat A (1989). Honey--a remedy rediscovered.. J R Soc Med, 82(7), 384 - 385.
    • Brown J, Marchant B, Zumla A (1989). Spontaneous subcapsular splenic haematoma formation in infectious mononucleosis.. Postgrad Med J, 65(764), 427 - 428.
    • Lulat A, Zumla A (1989). Malaria in spite of chemoprophylaxis.. J Infect, 19(2), 186 - 187.

    1988

    • McCarthy M, Zumla A (1988). DF-2 infection.. BMJ, 297(6660), 1355 - 1356.
    • Zumla A, Lipscomb G, Lewis D (1988). Sixth cranial nerve palsy complicating psittacosis.. J Neurol Neurosurg Psychiatry, 51(11), 1462 - .
    • Zumla A, Lipscomb G, Corbett M, McCarthy M (1988). Dysgonic Fermenter-type 2: an emerging zoonosis. Report of two cases and review.. Q J Med, 68(257), 741 - 752.
    • Williams W, Zumla A, Behrens R, Locniskar M, Voller A, McAdam KP, Isenberg DA (1988). Studies of a common idiotype PR4 in autoimmune rheumatic disease.. Arthritis Rheum, 31(9), 1097 - 1104.
    • Zumla A, Williams W, Shall S, Locniskar M, Leigh I, McAdam KP, Isenberg D (1988). Human monoclonal antibodies to phenolic glycolipid-1 from leprosy patients cross react with poly(ADP-ribose), polynucleotides and tissue bound antigens.. Autoimmunity, 1(3), 183 - 195.
    • Zumla A, Lewis D, Brown J (1988). Ciprofloxacin treatment of recurrent Salmonella typhimurium septicaemia in a splenectomized and immunosuppressed patient.. J Antimicrob Chemother, 21(6), 809 - 810.
    • Locniskar M, Zumla A, Mudd DW, Isenberg DA, Williams W, McAdam KP (1988). Human monoclonal antibodies to phenolic glycolipid-I derived from patients with leprosy, and production of specific anti-idiotypes.. Immunology, 64(2), 245 - 251.
    • McCarthy M, Zumla A (1988). DF-2 infection. May follow dog bites and hazardous to the immunosuppressed. British Medical Journal, 297(6660), 1355 - 1356.
    • Zumla A, Weyell R, Tettmar RE (1988). Legionnaires' disease: early lessons from 1988 London outbreak.. Lancet, 1(8597), 1275 - .

    1982

    • Zumla A, Voller A (1982). A serological study on primary hepatocellular carcinoma in Zambia.. Trans R Soc Trop Med Hyg, 76(4), 546 - 551.

    • ZUMLA A, Saadu A (). Human monoclonal antibodies. Production, uses and problems. In (Ed.), Monoclonal Antibodies: Production, engineering and clinical application (pp. 85 - 120). : .
    • ZUMLA A, Rowland-Jones S, McMichael A (). Lung immunology in AIDS patients.. In Zumla A, Miller RF (Ed.), Aids and Respiratory Medicine (pp. - ). : .
    • Rook GAW, Hernandez-Pando R, Zumla A (). Tuberculosis due to high-dose challenge in partially immune individuals:a problem for vaccination?. The Journal of Infectious Diseases, , - .
    • ZUMLA A (). Paediatric TB and the Human Immunodeficiency Virus Epidemic. In Zumla A (Ed.), Aids and Respiratory Medicine (pp. 345-350 - ). : .
    • ZUMLA A (). Sarcoidosis and Leprosy: a comparative perspective. In James DG (Ed.), Sarcoidosis and Other Granulomatous Disorders. (pp. - ). : .
    • ZUMLA A (). Markers of diseases activity in Tuberculosis. In Zumla A, Schaaf S (Ed.), Clinics in Chest Medicine (pp. - ). : .